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 A causative agent of malaria, Plasmodium falciparum, infects human red blood 
cells, where it utilises haemoglobin as a source of amino acids. The digestion of this 
protein is also essential for regulating the osmotic pressure and increasing space 
within the red blood cell for the rapidly growing parasite. Digestion of haemoglobin 
occurs in a specialised food vacuole, where different enzymes break down 
haemoglobin until aminopeptidases are able to cleave free amino acids from small 
peptide chains; two such aminopeptidases, PfA-M1 and PfA-M17, are implicated in 
this stage. Most of the current literature on these two enzymes focuses on developing 
drugs that inhibit their activity, but the essentiality and biological function of PfA-M1 
and PfA-M17 within the parasite is still unresolved.  
 This study utilised the robust and targeted CRISPR-Cas9 system in an attempt 
to create gene knockouts of PfA-M1 and PfA-M17, with the later returning transgenic 
parasites positive for knockout by PCR. Further investigation is required to see if the 
locus has been correctly deleted because despite limiting dilution cloning, wildtype 
parasites were also recovered in these populations. PfA-M1 was resistant to genetic 
disruption, suggesting it is essential to the erythrocytic cycle of the parasite lifecycle. 
In contrast to its potential genetic deletion, conditional knockdown of PfA-M17 
expression utilising the ribozyme system resulted in stalling of parasite growth at 
trophozoite stage, limited reinvasion capacity and eventual parasite death. The 
riboswitch system was also employed to create a PfA-M1 knockdown parasite line, 
which now requires generation of a clonal population before phenotypic analysis can 
be performed to tease out the function of this enzyme. Finally, four novel inhibitors 
developed against the two aminopeptidases were evaluated for their potency and 
effect on P. falciparum survival. All inhibitors impacted on parasite growth, with the 
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dual PfA-M1 and PfA-M17 inhibitors being the most potent, giving rise to the most 
severe phenotypes. Metabolomic analysis of wildtype P. falciparum parasites treated 
with one of the dual inhibitors and on transgenic parasites after knockdown of PfA-
M17 revealed an increase in the number of peptides, some of which could be linked 
to the alpha and beta chains of haemoglobin, suggesting that both PfA-M1 and PfA-
M17 are playing a role in this digestive pathway. Further work can now be performed 
to characterise these compounds in the hope to develop them as effective therapeutics 
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1.1 Malaria: statistics, species and control 
 Malaria is an infectious parasitic disease caused by protozoan apicomplexan 
parasites belonging to the genus Plasmodium. Prevalent throughout sub-Saharan 
Africa, South-East Asia and South America, Plasmodia claim up to half a million lives 
per year (WHO, 2017b). Over 70% of deaths due to malaria are of children under the 
age of five, while half the world’s population is currently at risk of contracting the 
disease (WHO, 2017b) . Five different species of Plasmodium are able to infect 
humans; P. falciparum, P. vivax, P. malaria, P. ovale and P. knowlesi. Although P. 
vivax has the highest infection rate globally, it is mostly excluded from the malaria-
endemic regions in Africa, and it only accounts for 1% of malaria-related deaths. 
Interestingly, P. knowlesi is characterised as a primate malarial species but it is also 
capable of  primate-to-human transmission (Cox-Singh et al., 2008). P. falciparum is 
the deadliest Plasmodium species, being responsible for ~99% of deaths worldwide 
and thus, not surprisingly, has attracted the majority of research interest and funding. 
Globally, over US$2 billion is invested every year into Plasmodium elimination and 
control, and as we move from elimination to eradication, the need for investment will 
only grow (Liu et al., 2017; Ta et al., 2014).  
 Spread through the infectious bite from female mosquitos of the Anopheles 
genus, Plasmodium has long evolved alongside both primates and humans, with 
symptoms recognised and described in humans for thousands of years (Cox, 2010). 
P. falciparum evolved from a zoonotic crossover from apes millennials ago (Agop-
Nersesian et al., 2008), and this long process of co-evolution with its host makes 
targeting and treating the parasite extremely difficult. Humans infected with 
Plasmodium fail to readily form sterilising, long-lasting immunity (Stanisic et al., 2015), 
and thus far many attempts to develop efficacious vaccines have been minimally 
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successful (Matuschewski, 2017; WHO, 2017a). Without a sterilising vaccine, 
therapeutics are necessary and long before Plasmodium was identified as the 
aetiological agent of malaria, quinine in the form of cinchona bark was used to combat 
fevers (Achan et al., 2011). Throughout the middle of last century, the closely related 
aminoquinoline chloroquine was used as a first line anti-malaria treatment. Both these 
drugs are now somewhat obsolete for treatment of falciparum malaria due to the rapid 
onset and spread of drug resistance (Spencer, 1985). The loss of these therapeutics 
drove the development of drugs equipped with new modes of action in an attempt to 
overcome parasite resistance, and in the 1970’s artemisinin was discovered 
(Krungkrai and Krungkrai, 2016). Its implementation added hope to the ideal of 
eliminating Plasmodium, and to this day artemisinin-based combinations therapies are 
recommended as the first-line treatment (WHO, 2017b).  
 While global mortality and morbidity due to malaria has decreased since the 
early 2000’s, treatment is again becoming increasingly difficult with the emergence of 
parasites that are resistant to all therapies, including artemisinin-combinations (Ataide 
et al., 2017).  The origin of artemisinin resistance has been traced to the greater 
Mekong region, and whilst delayed treatment response times to artemisinin have yet 
to be reported in Africa (Imwong et al., 2017), its emergence is of grave concern as 
treatment will become more difficult and it is only a matter of time before this therapy 
will be eventually lost. Although continued drug development has been of high priority 
in the past decade, there has been low success rates (Petersen et al., 2011). A number 
of approved drugs have been introduced without a thorough understanding of their 
mechanism of action and this in turn can impact the development and speed of 
parasite resistance (Cui and Su, 2009; Petersen et al., 2011). Notably, P. falciparum 
has developed resistance to modified drugs targeting recycled mechanisms of action 
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within five years of their introduction (WHO, 2017b). This highlights that new drugs 
targeting novel pathways are essential to maintaining the global gains that have been 
made thus far in combatting malaria. 
1.2 Plasmodium lifecycle 
 P. falciparum has a complex lifecycle, and includes both mosquito vectors and 
its human host. The bite from an infected female Anopheles mosquito results in the 
injection of parasites in the form of sporozoites into the dermis, where they then travel 
via the bloodstream to the liver (Cox, 2010; Richie et al., 2015). Once the sporozoites 
have infected hepatocytes, they undergo rounds of replication termed exoerythrocytic 
schizogony, leading to the production of thousands of uni-nucleated merozoites (Cox, 
2010). Once matured, these merozoites are once again released into the bloodstream 
where they are competent to invade red blood cells (RBCs). It is the intra-erythrocytic 
cycle that is responsible for the clinical manifestations of malaria, including fever and 
anaemia (Mohandas and An, 2012) (Figure 1.1). As a merozoite invades the RBC, it 
becomes encased in a vacuole, termed the parasitophorous vacuole (PV), and shortly 
thereafter it develops into a ring-stage parasite (Eksi and Williamson, 2011). This is 
followed by an intermediate trophozoite stage, which is when the parasite is rapidly 
growing and remodelling the host cell (Marti et al., 2005). Towards the end of its ~48 
hr cycle in the RBC, the parasite begins to replicate its DNA, forming daughter 
merozoites within a schizont (Marti et al., 2005). The cycle ends when the mature 
schizont ruptures and releases the merozoites, which can then go on to infect further 
RBCs (Bannister et al., 2000). A subset of these merozoites can also commit to 
becoming sexual stage parasites, which when ingested by a female mosquito during 
her blood meal, are capable of further development in the mosquito to propagate the 














Figure 1.1 Intra-erythrocytic cycle of the parasite Plasmodium falciparum 
(Adapted from (Marti et al., 2005) 
The erythrocytic cycle begins when a merozoite invades a red blood cell (RBC) and becomes 
encased in the parasitophorous vacuole (PV) that is surrounded by the parasitophorous 
vacuole membrane (PVM). From 0- 20 hours after invasion, the parasite is referred to a ring-
stage parasite. By 20 hours post-invasion, the parasite has developed a food vacuole (FV), 
which is where haemoglobin digestion occurs and is evident due to the formation of haemozoin 
crystals; the parasite is now in the early trophozoite stage. At 28-40 hours post-invasion, the 
parasite is a mature trophozoite; by this stage, extensive remodelling of the RBC has occurred, 
evident by formation of knob-like structures at the RBC membrane (dark green) and formation 
of membranous structures within the RBC (light green). The food vacuole is also larger. After 
>40 hours after initial invasion of a RBC, asexual reproduction has occurred and the so-called 
mature schizont is ready to release its daughter merozoites which are competent to invade 
other RBCs. N, nucleus; PV, parasitophorous vacuole; PVM, parasitophorous vacuole 




         0-20 hrs                                 20-28 hrs                                 28-40 hrs                                   >40 hrs     
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1.3 Haemoglobin digestion in P. falciparum  
 In order for the parasite to grow within a RBC it must acquire the appropriate 
nutrients. Haemoglobin (Hb) is the major constituent of RBCs, and is responsible for 
carrying oxygen around the human body. P. falciparum utilises Hb as its primary amino 
acid source, with the catabolism of this protein an essential process (Ball and McKee, 
1948). Approximately 16% of all free amino acids liberated from Hb digestion are 
utilised for protein synthesis (Krugliak et al., 2002; Liu et al., 2017; Rosenthal, 2002). 
The turnover of Hb is also implicated in regulating the osmotic pressure of the RBC, 
as well as providing room for the growing and replicating parasite (Lew et al., 2004).  
 Digestion of Hb takes place in a specialised food vacuole that forms early in the 
trophozoite stage of the lifecycle (Figure 1.2). This vacuole is distinctive due to a by-
product of Hb digestion called haemozoin, which is the crystallised form of the toxic 
metabolite haem, and which is readily visualised in Giemsa-stained blood smears by 
microscopy (Coronado et al., 2014). Even though the food vacuole is only evident as 
the parasites transitions into trophozoite stage, Hb digestion is thought to occur even 
in the ring stages of parasite development (Dluzewski et al., 2008). The cytoplasmic 
contents of the RBC are taken up by endocytic vesicles that potentially function as 
individual food vacuoles, and at very late ring stage these vesicles fuse together, 
making one large digestive compartment (Dluzewski et al., 2008).  
 The food vacuole itself is acidic and contains a number of different enzymes 
utilised in Hb digestion and the resultant release of free amino acids. Four aspartic 
proteases (plasmepsins) have been isolated and extensively characterised, with many 
possessing overlapping and redundant functions in P. falciparum (Harbut et al., 2011; 










Figure 1.2 Haemoglobin digestion in Plasmodium falciparum 
Haemoglobin (Hb) digestion occurs within an acidic food vacuole. Hb is broken down step-
wise into oligopeptides by plasmepsin and falcipain enzymes. Dipeptidyl aminopeptidase 1 
releases small/dipeptides. Free amino acids are finally released by aminopeptidases and 
these are used by the parasite for its own protein synthesis, as well as regulating osmotic 
pressure and creating space within the host cell. This step is thought to occur either in the 




early stages of Hb digestion, with the resultant globin polypeptides further degraded 
into small fragments or dipeptides by the enzyme dipeptidyl aminopeptidase 1 (Wang 
et al., 2011). From this stage, the final cleavage of free amino acids from Hb is thought 
to occur either inside or outside of the food vacuole by four aminopeptidases (Dalal 
and Klemba, 2007); aminopeptidase P (PfA-APP), an M1-family alanyl 
aminopeptidase (PfA-M1), an M17-family leucyl aminopeptidase (PfA-M17) and an 
M18-family aspartyl aminopeptidase (PfA-M18) (Lin et al., 2015).  
1.3.1 Aminopeptidases involved in Hb digestion 
 Aminopeptidases utilise a metal ion in their catalytic domain to polarise water 
molecules, which then have the ability to cleave amide bonds, freeing amino acids 
from peptide chains (Gavigan et al., 2001; Skinner-Adams et al., 2010; Taylor, 1993). 
P. falciparum PfA-APP is a prolyl aminopeptidase that can only cleave N-terminal 
residues when a proline lies at the carboxyterminal end of the amino acid to be 
cleaved, something the remaining three aminopeptidases implicated in late-stage Hb 
digestion are unable to do (Drinkwater et al., 2016a). Dalal and Klemba (2007) found, 
that when fused to a yellow fluorescent protein (YFP), PfA-APP localised to both the 
food vacuole and parasite cytosol by live cell imaging. The protein was also confirmed 
to have enzymatic function at an acidic pH representative of the food vacuole, 
suggesting that it may be active in this compartment. Any attempts to create genetic 
knockouts in P. falciparum were unsuccessful, suggesting that it is essential for 
parasite survival in the erythrocytic cycle (Dalal and Klemba, 2007). Saturation 
mutagenesis of the P. falciparum genome using the piggyBac transposon revealed no 
insertion events in Pfa-app, suggesting this gene is essential and thus a possible 
target for future drug development (Zhang et al., 2018). This is in contrast to the ability 
of the gene encoding the orthologous APP aminopeptidase to be knocked out in the 
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murine species, P. berghei (Lin et al., 2015); however, as this species grows in 
reticulocytes, which are immature RBCs that likely possess more nutrients for the 
parasite, the relevance of this finding to P. falciparum, which grows in mature RBCs, 
is still unknown.  
 PfA-M18 is an aspartyl aminopeptidase that exclusively cleaves glutamate and 
aspartate, and has been characterised as a potential drug target (Spicer et al., 2014; 
Ta et al., 2014). There have been mixed reports of the essentiality of the enzyme, with 
antisense-mediated knockdown resulting in a lethal parasite phenotype, including the 
rupturing of the food vacuole as well as accumulation of Hb (Teuscher et al., 2007); in 
comparison, saturation mutagenesis using piggyBac transposon found the gene to be 
dispensable (Zhang et al., 2018). Dalal and Klemba (2007) were also able to generate 
Pfa-m18 knockout parasites, thereby showing that parasites in the erythrocytic cycle 
do not require PfA-M18 for their survival. This is further supported by the findings that 
the gene encoding the orthologous enzyme in P. berghei can also be knocked out (Lin 
et al., 2015). PfA-M18 has been localised to both the parasite cytosol and PV, and 
encouragingly shows limited homology to the human analogue, thus potentially 
making it easier to target with therapeutics as potential off-target effects will be 
reduced (Dalal and Klemba, 2007). In addition to its implied role in Hb digestion, PfA-
M18 has been shown to bind to members of the RBC cytoskeleton. This was analysed 
using recombinant PfA-M18 in vitro in blot overlay assays, which showed the enzyme 
particularly interacted with spectrin, as well as a number of other erythrocyte 
membrane proteins (Lauterbach and Coetzer, 2008). Sequence analysis showed that 
the spectrin-binding region identified is not present in the sequence of Homo sapiens 
M18 aminopeptidase analogues and is missing from other Plasmodium species; the 
fact that this sequence is missing from other species may suggest it is playing a vital 
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role in P. falciparum infections only.  It is plausible that PfA-M18 has dual roles within 
the infected cell since genomic sequencing has revealed only ~14% of the parasites 
genes encode enzymes, which is much lower than expected (Gardner et al., 2002). 
However, as PfA-M18 has only been localised within the parasite and not within the 
infected RBC (Dalal and Klemba, 2007), and as PfA-M18 does not harbour sequences 
that direct export into the RBC, it is possible that these RBC proteins may not be 
targeted by PfA-M18 in vivo. Other digestive enzymes have also been implicated in 
the remodelling of the RBC cytoskeleton, including plasmepsin-II (Le Bonniec et al., 
1999) and falcipain-2 (Meenakshi et al., 2001), but again both were tested using 
recombinant proteins and as such it is possible that findings are not representative of 
natural targets.  
 PfA-M17 is a neutral metallo-aminopeptidase which almost exclusively cleaves 
leucine (McGowan et al., 2010). As human Hb does not contain isoleucine, large 
amounts of leucine are needed so that some of it can be exported from the parasite 
and RBC via an ATP-independent transporter in exchange for isoleucine from the 
serum (Liu et al., 2006; Martin and Kirk, 2007; Skinner-Adams et al., 2010); starvation 
of isoleucine leads to a growth hibernation phenotype that can only be recovered up 
to 72 hours post-starvation, after which the parasites die (Babbitt et al., 2012). PfA-
M17 has the ability to cleave a small subset of other amino acids, but its extremely 
high affinity for leucine indicates this is most likely its sole substrate in vivo (Stack et 
al., 2007). The gene encoding the M17 orthologue in P. berghei could be disrupted, 
although a decrease in replication rate was observed (Lin et al., 2015). Loss of this 
enzyme prevented the formation of haemozoin, which was not detected in the many 
food vacuoles that are present in P. berghei. The relevance of this finding to P. 
falciparum however is unknown given P. falciparum resides in mature RBCs, which 
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are less nutrient dense than reticulocytes. In contrast to the genetic studies performed 
in P. berghei, inhibition of PfA-M17 using specific compounds causes parasite death 
at the ring stage, although there is always the possibility that this is due to off-target 
effects; this was, however, further supported by the inability to recover parasites with 
a disrupted Pfa-m17 locus after piggyBac transposon insertional mutagenesis, 
suggesting it is essential in blood-stage growth (Zhang et al., 2018). M17 
aminopeptidases have also been the focus of research in other apicomplexan 
parasites, with the discovery that the orthologous genes are not essential in either 
Trypanosoma brucei (Timm et al., 2017) or Toxoplasma gondii, the latter a parasite 
closely related to Plasmodium (Zheng et al., 2015). Critically, however, neither T. 
brucei nor T. gondii utilise Hb as a nutrient source.  
 PfA-M1 is particularly interesting because of its large substrate specificity (Dalal 
et al., 2012) and multiple described localisations within the parasite (Dalal and Klemba, 
2007). Moreover, studies performed in P. berghei revealed that the orthologous M1 
aminopeptidase is essential for parasite survival (Lin et al., 2015). This was based on 
experiments in which two different constructs were transfected into three different 
parental lines in an attempt to knockout the gene, all of which were unsuccessful. As 
Plasmodium spp. are haploid and transfection is performed in the RBC stages, genes 
that are essential to this stage of the lifecycle will be refractory to gene knockout. This 
was further supported by the failed attempts made by Dalal and Klemba (2007) to 
disrupt PfA-M1 in P. falciparum using traditional transfection methods, where the 
efficacy of gene editing is much lower (de Koning-Ward et al., 2015). The use of an 
M1-selective inhibitor has also been shown to result in swelling of the food vacuole, 
accumulation of haemoglobin-derived oligopeptides and parasite death, suggesting 
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that PfA-M1 may be playing an essential role in blood-stage development (Rosati et 
al., 2017).   
 High-throughput piggyBac transposon insertional mutagenesis of P. falciparum 
revealed that Pfa-m1, like Pfa-app and Pfa-m17, was refractory to transposon 
insertion, indicating it is likely to be essential for blood-stage growth (Zhang et al., 
2018). While such mutagenic systems are untargeted, they provide a powerful 
approach to predict a gene’s essentiality; however, transposons may not always insert 
into the coding sequences of smaller genes, given that the frequency of transposon 
insertion in this study was approximately every 500 base pairs. Seeing the sequence 
coding for PfA-M1 is 3.2 kb and that of PfA-M17 is 1.8 kb, it is likely that the lack of 
transposons in these genes is because they are refractory to disruption.  Thus, given 
the potential roles of PfA-M1 and PfA-M17 in Hb digestion, which is critical for parasite 
survival, and the conservation of these enzymes across all Plasmodium species 
(McGowan et al., 2010), shedding new light on the function of these two proteins may 
lead to new and more efficacious therapeutics against malaria. 
1.3.2 Structure and kinetics of aminopeptidases PfA-M1 and PfA-M17 
 The first aminopeptidase was isolated from P. falciparum in the early 1980’s 
using high performance liquid chromatography (Vander Jagt et al., 1984). In this study, 
a metallo-aminopeptidase of approximately 100 kDa was discovered that could be 
inhibited by Bestatin, a well-known aminopeptidase inhibitor (Umezawa et al., 1976). 
Many years later, a protein belonging to the M1-family of zinc aminopeptidases was 
isolated from blood-stage parasites that corresponded to this previously characterised 
protein (Florent et al., 1998). The PfA-M1 gene encodes an approximate 120 kDa 
monomer protein, which harbours a hydrophobic region at its N-terminus and four 
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domains, with the catalytic zinc site deep within domain 2 (Drinkwater et al., 2016b; 
Jones et al., 2011; Skinner-Adams et al., 2010). The four domains form a classical 
bacterial aminopeptidase fold (Skinner-Adams et al., 2010), creating an entry and exit 
channel for substrates through domains 4 and 1, respectively (Jones et al., 2011). 
Using recombinant PfA-M1 purified via zinc-affinity chromatography, Dalal et al. (2012) 
determined the substrates most readily cleaved were small and basic, with most 
containing hydrophobic residues. However, enzymatic binding energies were found to 
be a fraction of what is required in order to accommodate a large array of side chains 
to enter through domain 4; in order to overcome this, PfA-M1 functions best at very 
high substrate concentrations (Dalal et al., 2012). More recently, Rosati et al. (2017) 
determined that two specific cap residues in domain 1 allow the enzyme to 
accommodate a range of side chains, thus enabling it to cleave a wide range of 
different amino acids (Rosati et al., 2017). PfA-M1 alone can readily cleave more than 
50% of the different amino acids in vitro, and it is the only aminopeptidase with the 
ability to cleave arginine within the parasite; this amino acid can be used to represent 
its overall function (Poreba et al., 2012).  
 Interestingly, the sequence of PfA-M1 also contains five alternate start codons, 
hinting perhaps to various functions for the different products generated by these 
transcripts, potentially across different stages of the lifecycle (Ragheb et al., 2011). 
Alternate functions have also been suggested through the exploration of the optimal 
pH of the enzyme. Allary et al. (2002) determined the optimal pH to be 7.4 using 
purified extracts from schizont stage parasites, but found the enzyme to be up to 40% 
active over a pH range of 5.8 - 8.6 (Allary et al., 2002). Purification via lysis and high 
performance liquid chromatography may result in conformational changes that effect 
enzymatic viability and function. A more recent study used a recombinant PfA-M1 to 
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investigate if this enzyme could have a sole function in an acidic environment (Ragheb 
et al., 2011). Kinetic studies found that enzymatic function was at 90% of starting 
capacity at a pH range over 5.0 to 8.5 after one hour, sufficient for amino acid 
cleavage. However, the recombinant protein produced in Escherichia coli did not 
contain the predicted first 191 amino acids of the protein sequence, which may have 
affected the folding of domain 1 of the protein, and thus the optimal pH. Isolation of 
the endogenous protein has proven difficult due to the processing steps that it appears 
to undergo after translation; proteins of 120, 96 and 68 kDa, all with enzymatic activity, 
were discovered in the erythrocytic stages in the late 1990’s. Florent et al. (1998) first 
discovered the 96 kDa and 68 kDa forms of the protein using polyacrylamide gel 
electrophoresis. Generation of rabbit anti-PfA-M1 antibodies revealed the same active 
site could be detected in the 96 and 68 kDa proteins as the 120 kDa form, confirming 
the latter as the precursor protein (Florent et al., 1998). Azimzadeh et al. (2010) were 
also the first to show that PfA-M1 is translated in the late-ring stage of the parasite 
lifecycle, earlier than previously reported, where it may also be playing an additional 
role, as well as being involved in the earliest stages of Hb digestion. 
 In comparison, PfA-M17 is a much smaller enzyme, estimated to have a 
molecular mass of 68 kDa. It is also a zinc aminopeptidase, but it contains two 
separate zinc-binding sites, one that can readily be exchanged for an array of other 
metal ions; however, disruption of the ‘tight-binding’ site produces a non-functional 
enzyme (McGowan, 2013; Thivierge et al., 2012). More recently, a third zinc binding 
site has been suggested, and it is proposed that this allows the enzyme to form an ‘off’ 
confirmation (Drinkwater et al., 2018). Its homo-hexamer structure accommodates six 
separate active sites on the surface of domain 2 (Drinkwater et al., 2016b; McGowan 
et al., 2010); these active sites are internalised within the enzyme in order to limit self-
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cleavage, with monomeric enzymes showing no activity (Drinkwater et al., 2018). 
Unlike PfA-M1, PfA-M17 is not processed, and it is found at concentrations of up to 18 
times higher than that of PfA-M1 in vivo (Gardiner et al., 2006; McGowan, 2013; Stack 
et al., 2007). Stack et al. (2007) found PfA-M17 to have an optimal functional pH of 
7.0, whilst also finding that the enzyme could still function at a slightly alkaline pH of 
8.5. Interestingly, a recombinant leucine aminopeptidase produced from P. vivax that 
shows considerable homology to PfA-M17 also demonstrated a preference for slightly 
alkaline conditions (Lee et al., 2010). The pH within the parasite cytoplasm remains 
neutral, while the food vacuole is an acidic compartment (Kuhn et al., 2007); this 
supports findings that PfA-M17 is a cytoplasmic enzyme (Dalal and Klemba, 2007). 
Analysis of its timing of expression is consistent with its involvement in Hb digestion, 
with concentrations being highest in trophozoite-stage parasites (Stack et al., 2007). 
In recent years, research has questioned whether PfA-M17 may harbour an additional 
function. Treatment with an optimised substrate-specific inhibitor resulted in parasite 
death in the early ring stage of the life cycle, before the development of a visual food 
vacuole (Harbut et al., 2011). Indeed, the presence of PfA-M17 mRNA (and PfA-M1) 
(Weißbach et al., 2017) at the ring stage indicates these proteins could be translated 
at this earlier stage (Stack et al., 2007). However, other studies have revealed that the 
internalisation of the RBC cytoplasm and Hb digestion already occur in mid-ring stage 
parasites, much earlier in the lifecycle than first thought (Bakar et al., 2010; Xie et al., 
2016). Thus, the earlier expression of PfA-M17 and PfA-M1 aminopeptidases, and the 
phenotypes resulting from their inhibition, may simply be a reflection of this. 
1.3.3 Processing and localisation of PfA-M1 and PfA-M17 
 Aminopeptidases are highly conserved amongst all life, with most existing in 
either a cytoplasmic or membrane-bound form (Gardiner et al., 2009; Taylor, 1993). 
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The PfA-M17 protein does not contain a transmembrane domain, consistent with the 
fact that it has only been localised to the cytoplasm of the parasite (Thivierge et al., 
2012). Interestingly, Dalal and Klemba (2007) found that by fusing PfA-M17 to YFP, 
the fusion protein not only localised to the parasite cytosol but also to small punctate 
structures in mature schizonts such that each daughter merozoite exhibited one 
punctate spot. However, the punctate localisation of PfA-M17 in the schizont was not 
observed when the protein was fused to a hemagglutinin (HA) tag and thus it is 
possible that the punctate YFP labelling is an artefact due to the large size of the fusion 
protein (Dalal and Klemba, 2007). Inhibition of PfA-M17 in a parasite line 
overexpressing the enzyme has been performed using the aminopeptidase inhibitor 
Bestatin; increased resistance to Bestatin was observed in this overexpressing line, 
indicating PfA-M17 is the target of Bestatin (Gardiner et al., 2006). As Bestatin is not 
effective at a pH< 6.0 and thus would not be active at the pH of the food vacuole, this 
is in keeping with PfA-M17 being located in the cytoplasm. However, function and 
inhibition of other metallo-aminopeptidases was not taken into consideration in this 
study, and it is possible that additive effects between the four aminopeptidases of P. 
falciparum may be occurring at different locations. 
 The localisation of PfA-M1 has been much more difficult to determine due to 
the number of processing steps that it appears to undergo. Proteins corresponding to 
120, 96 and 68 kDa have all been identified, with all having the same active site 
needed to cleave amino acids (Florent et al., 1998). The full length 120 kDa (p120) 
form of the protein contains a hydrophobic domain at its very N-terminus (Azimzadeh 
et al., 2010). However, it is unclear whether the hydrophobic domain acts as a signal 
sequence or whether it serves as a transmembrane domain to anchor the protein into 
the endoplasmic reticulum (ER) membrane. The fungal metabolite brefeldin A (BFA), 
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which specifically blocks transport from the ER to the Golgi apparatus, has been used 
to confirm that p120 traffics via the secretory pathway to the PV (Azimzadeh et al., 
2010), thus either the protein is secreted into the PV space or is anchored to the 
parasite membrane with the protein extruding into the PV space. Western blots 
performed on parasites after treatment with BFA confirmed that blocking the trafficking 
of the p120 form resulted in none of the smaller protein forms, also confirming it as the 
precursor protein (Azimzadeh et al., 2010). The 96 kDa (p96) form has been described 
in multiple studies by one group where it has been detected only in the PV, and its 
concentration seems dependent on the concentration of saponin used to lyse RBCs 
(Azimzadeh et al., 2010; Florent et al., 1998; Siddiqui et al., 1979). However, this 
species has not been characterised due to the inability to purify it, and it has not been 
detected by other investigators; thus, it is still unclear whether this form is an artefact. 
The 68 kDa (p68) processed form of PfA-M1 is believed to be the species involved in 
Hb digestion as it has only been associated with parasite fractions and is soluble, 
suggesting that it lacks the N-terminal hydrophobic domain (Azimzadeh et al., 2010). 
Fractionation methods were utilised by Azimzadeh et al. (2010) to purify food vacuoles 
from P. falciparum, where they found fractions of the p68 form of the protein localising 
to this compartment using polyclonal antibodies raised against recombinant p68 
protein in mice (Azimzadeh et al., 2010). This suggests that at least a portion of the 
p120 protein trafficking to the PV from the ER is eventually reaching the food vacuole, 
and is processed to the p68 form at some point during its trafficking (Figure 1.3).     
 Attempts to image PfA-M1 have thus been hampered by the inability to 
distinguish between these different processed forms. Using PfA-M1 polyclonal 
antibodies specific for two peptide domains within the transmembrane domain of the 
PfA-M1 sequence, Allary et al. (2002) demonstrated that PfA-M1 localises to the 
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periphery of the food vacuole. As these antibodies recognise residues that are present 
in the hydrophobic domain of the protein, this again suggests that the protein is 
inserted into the ER membrane, which traffics to the PM and eventually becomes part 
of the food vacuole membrane. An earlier study suggested that the enzyme localised 
to the parasite cytoplasm, as polyclonal antibodies raised against amino acid residues 
163–175 of the protein showed a diffused labelling pattern throughout the parasite 
which appeared to be excluded from the food vacuole (Florent et al., 1998). However, 
this could be representative of protein trafficking between the different compartments 
of the parasite, and may also be a result of fixing methods used. Ragheb et al. (2011) 
has subsequently confirmed that a number of fixing methods causes this protein to 
exhibit variations in cytoplasmic labelling, in comparison to live cell imaging of wild-
type parasites when PfA-M1 was genetically fused to an YFP epitope tag, in which it 
localised to the food vacuole (Dalal and Klemba, 2007). As this YFP was located at 
the C-terminus of the protein, it suggests that the removal of this to produce the p68 
form occurs within the acidic environment of the food vacuole. Other studies which 
have tagged the protein at the C-terminus with a smaller hemagglutinin (HA) tag have 
reported that this does not localise to the food vacuole, supported by the knowledge 
that the tag is degraded by the acidic environment of the vacuole itself (Ragheb et al., 
2011). This study also used polyclonal antibodies produced against recombinant PfA-
M1 in cryo-immunoelectron microscopy to show that the protein localised to the lumen 
of the food vacuole, again supporting previous findings (Ragheb et al., 2011). It should 
be noted that the metallo-aminopeptidase APP has also been identified as having both 
a cytoplasmic and food vacuole localisation (Dalal and Klemba, 2007; Ragheb et al., 








Figure 1.3 Hypothesised trafficking of PfA-M1 
(Adapted from (Azimzadeh et al., 2010; Klemba et al., 2004)) 
After PfA-M1 is translated by a ribosome, it is most likely embedded by its transmembrane 
domain into the membrane of the endoplasmic reticulum as the p120 form. The protein then 
traffics through the secretory pathway, with vesicles containing p120 then fusing with the 
PPM such that the protein now faces into the parasitophorous vacuole (the space between 
the PPM and PVM). It is here that the p96 form has been previously isolated. The double-
membrane (PPM and PVM) pinches off, enabling Hb from the RBC cytoplasm to be 
transported into the parasite, where it then migrates to the food vacuole. After fusion of this 
vesicle with the vacuole, PfA-M1 may be released together with Hb into the food vacuole, 
where it could be cleaved into the smaller p68 form of the enzyme (by unknown 
mechanisms). ER, endoplasmic reticulum; PPM, parasite plasma membrane; PVM, 





 Intriguingly, when PfA-M1 was fused to either an YFP or HA epitope tag and 
trafficking analysed in live and fixed P. falciparum parasites, respectively, p120 was 
also localised to the nucleus as well as to the food vacuole (Dalal and Klemba, 2007). 
Ragheb et al. (2011) further confirmed this using a polyclonal affinity-purified anti-PfA-
M1 antibody in cryo-immunoelectron microscopy (Ragheb et al., 2011). Whilst these 
results were surprising, given PfA-M1 had been assumed to play a cleavage role in 
Hb digestion, a nuclear localisation of a M1-family enzyme has been described for 
another apicomplexan species, Eimeria tenella, a parasite that causes disease in 
poultry, although its function is not yet known (Gras et al., 2014). Interestingly, E. coli 
also has aminopeptidases that localise to the nucleus, which are involved in site-
specific DNA recombination (Alén et al., 1997; Stirling et al., 1989). However, it should 
be taken into consideration that the processing and trafficking of PfA-M1 occurs 
through the ER, which is a structure that is closely associated with the nucleus 
(Azimzadeh et al., 2010). Another protein involved in Hb digestion is plasmepsin II, 
which localises to the food vacuole and has also been shown to traffic through the ER 
in this manner. Trafficking of a plasmepsin II-GFP fusion protein was shown to be 
blocked at the endoplasmic reticulum and nuclear envelope by BFA, suggesting that 
the relationship between these two sites may hard to distinguish. Without BFA 
treatment, plasmepsin II traffics to the PM as a membrane-bound protein, and can be 
seen in Hb-containing vesicles that eventually fuse with the food vacuole (Klemba et 
al., 2004). Meanwhile, in Trypanosoma brucei parasites, an M17 aminopeptidase that 
localises to the ER is thought to have a role in processing proteins that are to be 
trafficked to other destinations but is itself not trafficked further (Timm et al., 2017). 
With this in mind, further investigation is needed to clarify the exact role of the different 
processed forms of PfA-M1, as well as the potential function of a nuclear form of the 
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enzyme that could even be a product arising from a different start codon within the 
beginning of the PfA-M1 protein sequence.  
1.4 Towards targeting PfA-M1 and PfA-M17 with inhibitors 
 Inhibition of metallo-aminopeptidases generally focuses on blocking the metal 
ion used by the enzymes to hydrolyse peptide bonds. The reversible competitive 
inhibitor Bestatin was first used to characterise aminopeptidases in P. falciparum 
(Umezawa et al., 1976; Vander Jagt et al., 1984) and has been used over the years 
to determine structures and binding affinities of both PfA-M1 and PfA-M17 (Harbut et 
al., 2011). As mentioned previously, Bestatin functions optimally at a pH of 7.4, 
suggesting that it targets cytoplasmic versions of these enzymes. Its use results in a 
decrease in haemozoin production and isoleucine uptake, both indicators of Hb 
digestion, again indicating the roles of PfA-M1 and PfA-M17 in this essential process 
(Harbut et al., 2011). To determine the specificity of Bestatin, Gardiner et al. (2006) 
transfected parental parasites with a plasmid that led to the overexpression of PfA-
M17. As resultant parasites displayed resistance to the inhibitor, this suggested that 
Bestatin targets PfA-M17 rather than the PfA-M1 enzyme in vivo. Other metal 
chelating compounds also decrease the activity of PfA-M17, as they target the zinc 
ion within the enzyme. This has been shown for a recombinant form of the human 
Plasmodium species P. vivax M17 protein expressed in E. coli (Lee et al., 2010). 
Inhibition of the corresponding leucine aminopeptidase in the murine Plasmodium 
species P. chabaudi chabaudi with Bestatin, or with the closely related molecule 
nitrobestatin, has also been observed (Nankya-Kitaka et al., 1998); however, these 
drugs only show modest parasite killing. Novel phosphinate dipeptide inhibitors 
directed against Plasmodium M17 have also been tested in vivo, with some 
compounds able to reduce P. chabaudi chabaudi parasitemias by over 90% (Stack et 
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al., 2007). Harbut et al. (2011) were able to create a specific inhibitor to PfA-M17 using 
a Bestatin backbone with optimised side chains for the specific active sites on the 
surface of the molecule, which resulted in ring-stage arrest and parasite death before 
Hb digestion could be detected. As Hb uptake from the cytoplasm is now implicated 
to begin in the mid-ring stage of development, even before the detection of Hb 
digestion (Abu Bakar et al., 2010), this again supports the role of PfA-M17 in this 
essential process.  
 Similarly, specific inhibitors using a Bestatin backbone have been developed 
against PfA-M1 (Harbut et al., 2011).  Inhibition caused swelling of the food vacuole, 
a delay in maturation and eventually parasite death, but surprisingly only at the point 
of egress (Harbut et al., 2011). It is unknown what the cause of death is at this stage; 
it could be due to starvation, or stem from another mechanism. Isoleucine starvation 
for example, leads to parasites entering a hibernation state which can be maintained 
for ~72 hours after which parasites then die if isoleucine is not reintroduced into the 
media (Babbitt et al., 2012). Thus, after treatment with this PfA-M1 inhibitor, the 
parasites may be able to survive on endogenous amino acids until egress. 
Alternatively, PfA-M1 may play another role in addition to Hb digestion and the finding 
that PfA-M1 can be observed at the nucleus may have some bearing on why the 
schizont stage is affected. Using a different approach, Bounaadja et al. (2017) were 
also able to demonstrate the importance of selectively targeting PfA-M1. Using a novel 
amino-benzosuberone derivative that does not inhibit PfA-M17 up to a concentration 
of 100 µM, the authors were able to show parasite death both in vitro (P. falciparum) 
and in vivo (P. chabaudi chabaudi) (Bounaadja et al., 2017). Interestingly, they also 
noticed a change in food vacuole morphology in both the trophozoite and schizont 
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stage of the parasites, with swelling occurring; no morphological changes were seen 
in ring stage parasites. 
  There are some important considerations when designing inhibitors against 
aminopeptidases; one of the most important being the conservation of 
aminopeptidases between the parasite and host. The active sites of both PfA-M1 and 
human M1-aminopeptidases show significant homology, thus in silico screening 
against human M1 will be essential to determine the cross-reactivity between the two 
species (Sahi et al., 2014). The development of recombinant PfA-M1, as well as PfA-
M17, allows such predictions to be made early on in drug development (González-
Bacerio et al., 2014) and although both PfA-M1 and PfA-M17 may be involved in a 
number of different and distinct roles within the hosts RBC, there are also similarities 
between the structures of the enzymes themselves. The active site of both PfA-M1 
and PfA-M17 is within domain 2, with both enzymes containing a zinc-binding site 
highly suitable for inhibition (Ruggeri et al., 2015). Dual targeting of these sites is an 
attractive prospect for future development (Kannan Sivaraman et al., 2013). 
Drinkwater et al. (2016b) were able to produce potent dual inhibitors through the 
optimisation of specific enzyme structures, proving that these had the ability to kill 
multi-drug resistant parasites in vitro. Dual inhibition creates higher confidence in 
creating drugs that will be effective in a real-world situation, as the parasite will need 
to mutate multiple times to develop resistance. It may also be possible to repurpose 
drugs that target other aminopeptidases and hence reduce the magnitude of trials and 
effort that is fundamental to drug development. Drinkwater et al. (2015) showed that 
this was possible using the drug Tosedostat, an aminopeptidase inhibitor which is 
currently undergoing clinical trials for the treatment of blood disorders (Lowenberg et 
al., 2010). It was found that while the inhibitor bound to both P. falciparum enzymes, 
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it targeted different parts of them; PfA-M1 activity was inhibited by the compound 
binding the entry channel of the protein, while PfA-M17 was inhibited through 
interactions of the compound with both the zinc ion and the exit channel of the enzyme 
(Drinkwater et al., 2015). Dual inhibition targeting different mechanisms of two different 
enzymes would be ideal, as mutation rates that lead to drug resistance would take 
much longer to develop. So far, inhibition studies with these drugs has been performed 
only on blood stages of the parasite, with the greatest efficacy determined in the late 
ring and trophozoite stages (Gavigan et al., 2001). 
1.5 Genomic editing of P. falciparum 
 Underpinning the restricted ability to study both the function and localisation of 
the PfA-M1 and PfA-M17 enzymes are the difficulties faced when attempting to edit 
the P. falciparum genome. While stable transfection was first described in 1995, 
efficiencies are still extremely low (<1 in 106 parasites transfected) and as such 
transgenic parasite lines take months to generate (Sidhu et al., 2002; Wu et al., 1995; 
Wu et al., 1996). These methods rely on a chance break in the genome to occur, with 
repair only possible through homologous recombination (de Koning-Ward et al., 2015); 
when targeting sequences are fused to epitope tags or reporter genes, or selectable 
markers are contained within the targeting regions used for homologous 
recombination, the parasite will then incorporate these at that gene locus as well. After 
initial transfection, parasites will often replicate the introduced plasmids as episomes, 
requiring an extended period of cycling in the absence and then presence of the 
selection drug to enrich for parasites in which integration has occurred. Following this, 
the cultures are cloned via serial dilution to ensure that any further analysis is 
undertaken on a pure population of transgenic parasites.  
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 In the past few years, the advent of the CRISPR-Cas9 system has fast-tracked 
the generation of transgenic parasites because it enables the guided direction of 
double-strand breaks by the Cas9 endonuclease (Makarova et al., 2011). CRISPR 
stands for clustered regularly interspaced short palindromic repeats, and was 
discovered as a form of adaptive immunity in bacteria to avoid infection from foreign 
DNA viruses (Makarova et al., 2011). Specific RNA guides are designed to be 
homologous to a region of interest in the genome, which then targets the Cas9 DNA 
nuclease to that region to make a double stranded break. In Plasmodium, these breaks 
can only be repaired via homologous recombination with a template that has been 
transfected into the parasites along with the Cas9-containing vector; parasite death 
will occur without recombination, as this is the only method by which P. falciparum can 
mend such damage. Using the CRISPR-Cas9 system, positive edits of the P. 
falciparum genome can occur in as little as two weeks; gene knock-outs as well as 
knock-ins are now both possible in P. falciparum using this system (Ghorbal et al., 
2014). The integration of CRISPR-Cas9 editing and conditional regulation 
mechanisms to produce transgenic parasite lines in a timely fashion to study essential 
parasite genes is an exciting prospect for the future. 
 As P. falciparum is a haploid organism and transfection is performed on the 
RBC stage of the parasite lifecycle, parasite genes that are essential to this stage will 
not be able to be targeted for gene deletion, as this will result in parasite death. 
Conditional gene regulation systems are an attractive way to overcome such issues, 
with a number of mechanisms currently in use in P. falciparum (de Koning-Ward et al., 
2015). Conditional systems work at either the gene level, the transcriptional level, or 
at the post-transcriptional level, and work to reduce the level of protein expression 
within the parasite. One conditional system that is easy to employ is the riboswitch 
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method, which involves the introduction of a ribozyme sequence into the mRNA 
immediately downstream of the coding sequence. In this system, the addition of 
glucosamine activates the ribozyme to cleave the mRNA, thus destabilising the mRNA 
and reducing the level of translated protein (Prommana et al., 2013). Typically, this 
system leads to up to 90% reduction in protein levels and the consequences will 
depend on whether there is sufficient protein left to retain function within the parasite; 
this is particularly important when assessing proteins that function as enzymes, as low 
expression levels may still be adequate for function and thus parasite survival. 
Phenotypic analysis after knockdown will lead to insights into the functions and 
essentiality of the targeted protein.  
1.6 Conclusion and significance 
 If both PfA-M1 and PfA-M17 are essential to P. falciparum then they are 
attractive targets for future drug development, perhaps against a wide range of human 
malaria species, but there is more research required to validate these as drug targets. 
The human M1 aminopeptidase and PfA-M1 show significant homology in silico (Sahi 
et al., 2014); whether this is the case for PfA-M17 is yet to be determined. This 
characterisation is important to ensure inhibitors are designed to be selective for 
Plasmodium aminopeptidases, thus minimising off-target effects in vivo. Although 
studies performed in the murine parasite P. berghei have revealed the orthologous 
M17 enzyme is non-essential for parasite survival, its redundancy may be species 
specific. P. falciparum has developed more complexity in its Hb digestion pathway but 
potentially there is also gene redundancy in the system. Whilst failure to knock-out 
both enzymes PfA-M1 and PfA-M17 in P. falciparum using traditional transfection 
methods suggests that both enzymes play essential roles, the fact that P. falciparum 
is notoriously harder to genetically manipulate means that this may be due to technical 
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failures in transfection. The introduction of newer gene editing methods will not only 
allow transgenic parasite lines to be recovered quicker if the locus can be edited, but 
by combining these tools with conditional gene expression approaches it will be 
possible to provide a conclusion as to the essentiality of these two aminopeptidases.  
 Aminopeptidase involvement in Hb digestion has been partially characterised, 
but PfA-M1 and PfA-M17 are now implied to have additional activities based on the 
discoveries that PfA-M1 also localises to the nucleus, and PfA-M17 is present in 
rupturing merozoites. Interestingly, much higher concentrations of PfA-M17 are found 
in the parasite compared to PfA-M1, thus the former may be able to complement the 
function of PfA-M1 in Hb digestion if the latter is inhibited, or it may have an additional 
role in parasite development. Alternatively, as PfA-M1 can cleave leucine, which 
appears to be the sole substrate of PfA-M17 in vivo, PfA-M1 may be able to 
complement its role in Hb digestion. Early parasite death after the inhibition of PfA-
M17 suggests that it has an important role in haemoglobin digestion at this early stage 
or could be harbouring an additional role, while inhibition of PfA-M1 also results in 
parasite death but only at the point of egress. As yet, a global view of the role of these 
aminopeptidases in the blood stages of the parasite lifecycle are yet to be thoroughly 
investigated in P. falciparum. It is only once complete characterisation of these 
enzymes has been performed that the real potential of targeting these enzymes with 
therapeutics can be realised.  
1.7 Hypothesis and aims 
 The hypothesis of this project is that both PfA-M1 and PfA-M17 are involved in 
haemoglobin digestion within the erythrocytic cycle of P. falciparum, but only PfA-M1 
is essential for survival. Thus, the use of dual inhibitors to target both PfA-M1 and PfA-
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M17 will result in parasite death, but selective inhibition of PfA-M17 will not result in 
parasite death. 
The aims of this project are: 
• To attempt to genetically delete PfA-M1 and PfA-M17 using CRISPR-Cas9 to 
determine if they encode essential proteins in P. falciparum; 
• To determine the function and localisation of PfA-M1 and PfA-M17 by epitope 
tagging and regulating gene expression using a ribozyme knock-down method; 
• To determine the EC50 of four novel inhibitors designed to target PfA-M1 and/or 




































Equipment and reagents used in the project were supplied from the following 
companies: 
• Amresco     Solon, OH, USA 
• Astral      NSW, Australia 
• BioRad     Hercules, CA, USA 
• Fujifilm     Minato, Tokyo, Japan 
• GE Healthcare    Fairfield, CT, USA 
• Hospira     Lake Forest, IL, USA 
• Integrated Sciences    Georgia, USA 
• Interpath     Vic, Australia 
• Invitrogen     Groningen, The Netherlands 
• Jacobus Pharmaceuticals   Princeton, NJ, USA  
• Life Technologies    Carlsbad, CA, USA  
• Merck      San Diego, CA, USA 
• Millipore     Billerica, MA, USA 
• Miltenyi Biotec    Auburn, CA, USA 
• New England Biolabs   Ipswich, MA, USA   
• Nikon      Minato, Tokyo, Japan 
• Olympus     Shinjuku, Tokyo, Japan 
• Promega     Fitchburgm WI, USA 
• Provet      QL, Australia 
• Sigma      St Louis, MO, USA 
• Thermo Scientific    Rochester, NY, USA 
31 
 
2.2 Ethics statement 
 All experiments using human blood supplied by the Australian Red Cross Blood 
Service were performed in accordance with the Australian Government and National 
Health and Medical Research Council Australia code of practice and were approved 
by Deakin University (Approval 2014-283). 
 
2.3 Molecular cloning 
2.3.1 Programs for DNA and protein sequence analysis 
 DNA and protein sequences of P. falciparum were sourced from the 
Plasmodium Genomics Resource Database, PlasmoDB 
(http://plasmodb.org/plasmo/) (Aurrecoechea et al., 2009). In silico design of 
oligonucleotides, as well as analysis of DNA polymerase chain reactions (PCR), 
restriction digests and DNA ligations were all performed using Serial Cloner, version 
2.6.1 (Serial Basics). Oligonucleotides were further analysed by OligoCalc, version 
3.27 (Kibbe, 2007). CRISPR guide RNA sequences were designed using Benchling 
(https://benchling.com/crispr). 
2.3.2 Oligonucleotides 
 All oligonucleotides used in this study were supplied by Sigma and are listed in 
Table 2.1. Oligonucleotides were stored at -20oC.  
2.3.3 Plasmid preparations 
 Plasmid DNA was prepared from 2 mL or 200 mL (Miniprep and Maxiprep 
respectively) bacterial cultures of transgenic Escherichia coli grown in LB broth 
(Amresco) containing 100 µg/mL ampicillin (Sigma). These cultures were grown 
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overnight (16 hrs) at 37oC with constant agitation at 200 rpm. Plasmid DNA was 
purified using the PureLink Quick Plasmid Miniprep Kit or PureLink HiPure Plasmid 
Maxiprep Kit (Invitrogen) following the manufacturer’s instructions. Plasmid DNA was 
eluted in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0) and the concentration 
was determined using a Nanodrop 2000c spectrophotometer (Thermo Scientific) 
before being stored at -20oC. Plasmids used in this study are outlined in Table 2.2.  
2.3.4 Amplification of DNA by PCR 
 DNA fragments were amplified from genomic DNA isolated from wildtype P. 
falciparum parasites or transgenic P. falciparum parasite lines (as described in Section 
2.5.2). PCRs were performed using either PhusionTM High-fidelity or Taq DNA 
polymerase (New England Biolabs) according to manufacturer’s instructions. Briefly, 
reactions were carried out in a volume of 20 µl or 50 µl in 1 x PCR buffer containing 
50 - 100 ng of template DNA, 10 mM of forward and reverse oligonucleotides, 250 µM 
dNTP’s and 1 unit of polymerase. Each PCR was carried out in a C1000TM 
thermocycler (BioRad) using a variety of conditions. For PCR amplification using Taq 
polymerase: initial denaturation at 95oC for 30 seconds, followed by 35 rounds of 
denaturation at 95oC for 30 seconds, annealing at 48oC for 30 seconds and extension 
at 62oC for 1 minute per kilobase. A final extension at 68oC for 5 minutes completed 
the reaction. For PCR amplification using PhusionTM: initial denaturation at 98oC for 
30 seconds, followed by 35 rounds of denaturation at 98oC for 30 seconds, annealing 
at 52oC for 30 seconds and extension at 62oC for 1 minute per kilobase. A final 
extension at 68oC for 5 minutes completed the reaction. Reactions were prepared on 
ice and stored at 4oC.  
2.3.5 Restriction enzyme digest and dephosphorylation 
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 Restriction digests were performed on 500 ng - 4 µg of DNA in 20 µL reactions. 
Recommended buffers for each enzyme were used at a 1 x concentration, containing 
1 x bovine serum albumin (BSA) (New England Biolabs). Appropriate restriction 
enzymes were used at 1 - 2 units, and reactions incubated at 37oC for 2 hours. 
Digested plasmids to be used in ligations were also treated with Antarctic Phosphatase 
(New England Biolabs) for an additional 30 minutes after restriction enzyme digest to 
prevent self-ligation. The phosphatase was then heat inactivated at 80oC for 2 
minutes.  
2.3.6 CRISPR Guide annealing 
 CRISPR guide annealing was performed in 10 µl total reactions. 
Complimentary guides at 100 µM each were annealed in 1 x ligation buffer (New 
England Biolabs) containing 400 units of T4 kinase and 1 mM of ATP in Milli Q water. 
Reactions were carried out in a C1000TM thermocycler (BioRad) using the following 
conditions: 37oC for 30 minutes, followed by 94oC for 5 minutes, followed by reduction 
of temperature by 5oC per minute until 25oC, after which the product was stored at 
4oC. 
2.3.7 DNA ligation into the Cas9 Vector 
 Ligations were performed in 10 µL reactions, using 50 ng of the appropriate 
Cas9 vector. Annealed CRISPR guides from Section 2.3.6 were diluted 1:200 in Milli 
Q water and 1 µl was used per reaction, which consisted of 400 units of T4 DNA ligase 
and 1 x ligase buffer (New England Biolabs) in Milli Q water. The same reaction but 
without the annealed oligonucleotides was used as a negative control. Each reaction 
was incubated at room temperature for 20 minutes before bacterial transformation.  
2.3.8 DNA ligation by HIFI Assembly 
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 Ligations were performed in 20 µl reactions, using 10 µl of the NEBuilderR 2x 
HIFI DNA Assembly Master Mix (New England Biolabs). Vector and insert(s) were 
used at a 1:2 molar ratio respectively, with the remaining volume made up with Milli Q 
water. The same reaction but without insert DNA was used as a negative control. The 
reaction was incubated at 50oC for a range of 45 minutes to 4 hours, before being 
stored at 4oC.  
2.3.9 Bacterial transformation 
 E. coli XL-10 Gold competent cells stored at -80oC were thawed on ice, of which 
100 µl was used per transformation. Between 2 - 10 µl of ligation reaction, as outlined 
in either 2.3.7 or 2.3.8, was incubated with the cells for 30 minutes on ice before being 
heat shocked at 42oC for 45 seconds. The cells were then incubated on ice for 2 
minutes after which 900 µl of LB broth (Amresco) was added. The cells were then 
allowed to recover at 37oC for 1 hour with constant agitation at 200 rpm. Once 
recovered, cells were centrifuged at 5,000 g for 2 minutes and 900 µl of supernatant 
was removed. The remaining pellet was resuspended and plated onto an LB agar 
plate (Amresco) containing 100 µg/mL of ampicillin (Sigma) before being incubated at 
37oC overnight. Negative control ligations were also transformed and used as 
transformation controls. 
2.3.10 DNA sequencing  
 DNA for sequencing was prepared by adding 1 µg of plasmid DNA and 250 mM 
of an oligonucleotide specific to the required sequence to a final volume of 12 µl with 
Milli Q water. Sequencing was performed by the Australian Genome Research Facility 
(AGRF) using the Big Dye Termination (BDT) protocol. Sequencing was analysed 
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using ApE (M. Wayne Davis, University of Utah) and Serial Cloner version 2.6.1 (Serial 
Basics).  
2.3.11 Agarose gel electrophoresis  
 PCR products and plasmid digests were visualised on 1 % (w/v) agarose gels 
(Amresco). SybrSafe (Invitrogen) was added at a 1:25,000 concentration before the 
setting of the gels so that DNA could be visualised using a Chemidoc XRS UV 
transilluminator (BioRad). Loading buffer (10 % (v/v) glycerol, 0.01 % (w/v) 
bromophenol blue and 10mM EDTA) was added to samples at a 1:6 ratio before 
samples were added to the gel. Electrophoresis was performed at 100 - 150 V for 
between 30 minutes and 3 hours. 2.5 µL of 1 kb Plus DNA ladder (New England 
Biolabs) was run alongside samples to estimate the size of the fragments.  
2.3.12 Ethanol precipitation 
 DNA isolated from maxiprep(s) was resuspended in sterile TE buffer (10 mM 
Tris-HCl and 1mM EDTA), before the desired amount (30 - 100 µg) was resuspended 
in 2.5 x 100 (v/v) % ethanol and 0.1 x 3 M sodium acetate (pH 5.2), and stored at -
20oC overnight.  DNA was pelleted by centrifugation at 17 000 g at 4oC for 30 minutes, 
before being washed in 80 % (v/v) ethanol and allowed to air dry. Finally, the DNA was 
resuspended in sterile TE buffer. 
 
2.4 Plasmodium falciparum Applications  
2.4.1 Culturing P. falciparum 
 P. falciparum (strain 3D7 or transgenic line) parasites were cultured in complete 
media containing RPMI 1640 medium (Life Technologies), 20 mg/L gentamicin, 50 
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mg/L hypoxanthine, 25 mM sodium bicarbonate, 0.25% (w/v) Albumax (Life 
Technologies) and 5 % (v/v) heat-inactivated human serum. Parasites were cultured 
in O- human RBCs at 3 – 4 % (v/v) haematocrit. Parasite cultures were maintained at 
37oC at atmospheric conditions of 5 % CO2 and 1 % O2 in N2. Parasitemia counts 
(percentage of infected erythrocytes) were performed on thin blood smears made on 
glass slides and fixed with methanol for 10 seconds and then stained with Giemsa 
(1:10 dilution in water; Merck) for 5 - 10 minutes. A minimum of 1000 erythrocytes 
were counted. 
2.4.2. Freezing of P. falciparum cultures 
 Cultured parasites predominantly at ring stage were frozen in liquid nitrogen in 
1 mL aliquots. For this, 10 ml cultures were centrifuged at 350 g for 5 minutes before 
being resuspended in 3 ml malaria freezing solution (28% (v/v) glycerol, 3% (w/v) D-
sorbitol (Sigma) and 0.65% (w/v) sodium chloride in Milli Q water). Aliquots were 
immediately stored in cryovials in liquid nitrogen. 
2.4.3 Thawing of frozen P. falciparum lines 
 Aliquots frozen in liquid nitrogen were removed and transported on dry ice. Vials 
were then warmed with constant movement in a 37oC water bath. Once thawed, the 
material was added to equal volumes of pre-warmed malaria thawing solution (3.5% 
(w/v) sodium chloride) and centrifuged at 450 g for one minute. The supernatant was 
removed and the pellet washed three times in thawing solution to remove excess 
freezing solution before being resuspended in complete culture medium adjusted to a 
final haematocrit of 3 %. 
2.4.4 Synchronisation of P. falciparum 
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 Synchronisation of parasites was typically performed using D-sorbitol (Lambros 
and Vanderberg, 1979). For this, parasite cultures were pelleted at 350 g for 5 minutes 
and then resuspended in half the initial culture volume in pre-warmed 5% (v/v) D-
sorbitol (Sigma) and incubated at 37oC for 5 - 10 minutes. Cultures were spun again 
and the pellet washed two to three times with complete media to remove residual 
sorbitol. As sorbitol will lyse any RBC infected with older parasites (trophozoites and 
schizonts), this process allows for the specific selection of ring stage parasites (i.e. 
parasites up to 20 hour post-invasion stage).         
 To achieve tighter synchronisation of parasites, sorbitol synchronised parasites 
were incubated with heparin (Hospira; 30 IU/mL) to inhibit invasion of merozoites that 
burst from RBCs (Kobayashi and Kato, 2016). Once late-stage schizonts were 
observed, heparin was washed out using complete media before parasites were 
returned to culture for another 4 hours, allowing reinvasion to occur. After this time, 
infected RBCs were again sorbitol synchronised to lyse any remaining schizonts, 
providing a select window of reinvasion to occur, such that all remaining parasites 
were between 0 - 4 hours post-invasion stage.  
2.4.5 Transfection of P. falciparum 
 DNA for transfection (30, 70 or 100 µg) was ethanol precipitated and 
resuspended in 30 µL pre-warmed sterile TE buffer as per Section 2.3.12. Sorbitol 
synchronised, wildtype 3D7 P. falciparum parasites at approximately 5 % rings and 3 
% haematocrit in 10 mL were pelleted at 1500 g for 5 minutes, and the supernatant 
was removed. The parasite pellet was then resuspended in 370 µL pre-warmed sterile 
Cytomix buffer (120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2 10 mM 
K2HPO4/KH2PO2 and 25 mM HEPES pH 7.6). DNA was added to this mixture and 
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transferred to a 2 mm electroporation cuvette for transfection using a Biorad Gene 
Pulser XcellTM electroporator (program settings: 310 V, 950 µF and infinite resistance). 
Parasites were then immediately placed back into culture and once blood settled they 
were again fed with complete media. The following day, the parasites were placed 
under drug selection with 2.5 nM WR99210 (Jacobus Pharmaceuticals) to select for 
transfected parasites that express the human dihydrofolate reductase (hDHFR) drug 
selection cassette. Transfectants were typically visible via blood smear 18 - 30 days 
later.     
2.4.6 Cloning of transgenic parasite lines 
 Transgenic parasite lines were cloned out by limiting dilution to create 
genetically identical populations absent of wildtype parasites. Parasites were cultured 
in 96-well plates (as described in Section 2.4.1) at 2 % (v/v) haematocrit and 
mathematically calculated to contain either 0.3, 1 or 3 parasites per well. Briefly, the 
number of RBC’s per millilitre was determined using a haemocytometer and was used 
alongside the parasitemia to dilute cultures to the appropriate number of parasites, 
which was then aliquoted into a 96-well plate. Media was replaced every 5 days and 
chambers were gassed every 2 days; on day 10, WR99210 drug selection was 
applied. On day 15, cultures were checked for parasites in blood smears by Giemsa 
staining and transferred to 6-well plates where they were outgrown, frozen and 
genotyped via PCR.  
 
2.5 Analysis of transfectants 
2.5.1 Saponin lysis of infected RBCs 
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 Cultures at approximately 5 % parasitaemia were centrifuged at 350 g for 5 
minutes, and supernatant was removed. Infected RBC were lysed in 0.05 % (w/v) 
saponin in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, 
pH 7.4) (containing 1x protease inhibitor if pellet was used for downstream protein 
analysis). Lysed parasites were spun at 17,000 g at 4oC and washed in cold PBS until 
supernatant was clear. Pellets were stored at -20oC for downstream applications.    
2.5.2 Isolation of P. falciparum genomic DNA 
 Genomic DNA was extracted from wildtype parental and transfected parasites 
for analysis. Parasite pellets after saponin lysis were resuspended in 500 µL of TNE 
lysis buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA and 1.0 % (w/v) SDS, pH 8.0), 
with 10 µl of 10 mg/mL RNase A (Invitrogen) added and the mixture incubated at 37oC 
for 30 minutes. After incubation, 100 mg/mL of Proteinase K (Astral) was added and 
the mixture was further incubated at 37oC for 40 minutes. DNA extraction was 
performed by adding equal volume of 25:24:1 phenol:chloroform:isoamyl alcohol 
(Sigma) followed by centrifugation at 17000 g for 5 minutes; this step was repeated 
three times on the DNA-containing phase. The DNA was then precipitated by ethanol 
precipitation (see Section 2.3.12). 
2.5.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Protein from parasites obtained after saponin lysis of infected RBC were 
reduced by the addition of sample buffer containing 1 % (w/v) SDS, 10 % (v/v) glycerol, 
1 mM EDTA, 50 mM dithiothreitol (DTT), 0.005 % (w/v) bromophenol blue and 50 mM 
Tris HCl (pH 6.8) and incubation at 95oC for 5 minutes. Samples were clarified by 
centrifugation at 17,000 g for 5 minutes and loaded onto a 10 % SDS-PAGE gel. 
Precision PlusTM Protein standards (Biorad) were run alongside samples to estimate 
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molecular mass of the protein bands that separated. Gels were run at 150 V for 1 - 2 
hours in 1 x SDS-PAGE buffer (25 mM Tris base, 192 mM Glycine and 0.1 % (w/v) 
SDS).  
2.5.4 Western blotting  
 Electrophoresed proteins were transferred onto nitrocellulose blotting 
membrane (0.45 um pore size; GE Healthcare) using the Trad-Blot® TurboTM Transfer 
System (BioRad). The transfer was performed using the HIGH MW protocol for 10 
minutes in the presence of Trans-Blot® Turbo™ 5x Transfer Buffer containing 20 % 
(v/v) ethanol.  
 The nitrocellulose membrane was blocked for 2 hours in PBS containing 3 % 
(w/v) BSA. Primary antibody was diluted in blocking solution and applied to the 
membrane for 2 - 18 hours at 4oC, rocking at 30 rpm before washing three times for 5 
minutes in wash buffer (PBS with 0.05 % Tween-20 (Invitrogen)). Membranes were 
probed with horseradish peroxidase-conjugated secondary antibodies (Millipore; 
1:10,000 dilution in blocking solution) for 45 - 60 minutes rocking at 30 rpm and 
washed three times in wash buffer. ClarityTM ECL Western blotting substrate (BioRad) 
was used for detection according to manufacturer’s instructions. Membranes were 
imaged using a LAS-4000 Luminescent Image Analyser (Fujifilm) and band intensity 
determined using ImageJ software (NIH, version 1.51r). When required, membranes 
were stripped for re-probing using RestoreTM Western Blot Stripping Buffer (Thermo 
Scientific) as per the manufacturer’s instructions. Primary antibodies used in this study 
are outlined in Table 2.3.      
2.5.5 Immunofluorescent assay 
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 Transgenic parasites were fixed onto glass slides with acetone:methanol 
(90:10) for 2 minutes at -20oC and allowed to air dry at room temperature. Slides were 
then stored at -20oC until analysis. For immunofluorescent assays, slides were thawed 
at room temperature and blocked in PBS containing 1 % (w/v) BSA for 1 hour. Primary 
antibodies in blocking buffer were applied at concentrations outlined in Table 2.3 for 
90 minutes, before three 5 minute washes in PBS. The appropriate AlexaFluor 
488/568-conjugated secondary antibodies (1:1000) (Life Technologies) in blocking 
buffer was then applied for 45 minutes, and the slides were again washed three times 
in PBS. Cover slips were then mounted with Prolong Gold Antifade reagent containing 
4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies) and allowed to incubate 
overnight at 37oC. Images were taken on a Nikon Eclipse Ti2 microscope at 100 x 
magnification under oil immersion and processed using Photoshop (Adobe). 
2.5.6 Preparation of P. falciparum material for metabolomic analysis 
 Heparin synchronised parasites (as described in Section 2.4.4) were allowed 
to re-invade for 4 hours and then sorbitol synchronised to lyse remaining schizonts. 
Cultures were then treated with anti-malaria drug MIPS1788 at a final concentration 
of 390 nM or with 2.5 mM glucosamine (GlcN) or vehicle control. Parasites treated 
with GlcN were allowed to reinvade into the next cycle before being harvested at ~20 
hour old trophozoites, whereas for the MIPS1788 treatment, drug was added to the 
cultures for one hour when parasites were at ~20 hour old trophozoites before being 
harvested. Cultures were spun down at 1500 g, and the pellet resuspended in 10 mL 
of chilled PBS prior to cooling to between 4 - 6oC in an ethanol-dry ice bath to quench 
metabolism; spent media (supernatant) was also retained for further analysis. The rest 
of the procedure was performed at 4oC. 
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 Infected RBCs were purified away from uninfected RBCs via magnet 
purification using MACS columns (Miltenyi Biotec) and then eluted in 20 mL of cold 
PBS. The number of parasites were then calculated so that an equal number of 
infected RBCs could be aliquoted into 1.5 ml microcentrifuge tubes. Samples were 
centrifuged at 650 g for 3 minutes, the supernatant was then removed and the pellet 
washed in 500 µL of ice cold PBS. Samples were again centrifuged at 650 g for 3 
minutes and all PBS was removed. Pellets were resuspended in 150 µL of extraction 
buffer (50 mL methanol spiked with 10 mM PIPES, 10 mM CHAPS and 10 mM Tris) 
and quickly resuspended. Tubes were incubated on a vortex mixer for 1 hour before 
being centrifuged at 17,000 g for 10 minutes; 150 µL of the supernatant was aliquoted 
into new centrifuge tubes and retained for analysis. 15 µL of the supernatant from all 
samples was also pooled and analysed, as was spent media from the original parasite 
cultures (prepared as described above). Samples were stored at -80oC and 
transported on dry ice to the Monash Institute of Pharmaceutical Sciences (MIPS) 
where the analysis was performed.  
2.5.7    Metabolomics LC-MS analysis and data processing  
 Untargeted liquid chromatography – mass spectrometry (LC-MS) analysis was 
performed as previously described (Creek et al., 2016; Siddiqui et al., 2017) by Dr. 
Ghizal Siddiqui at MIPS. Briefly, metabolite samples were separated on a ZIC-pHILIC 
column, (5 µm, 150 x 4.6 mm, Merck) with a Dionex Ultimate 3000 UHPLC system 
(ThermoFisher) using 20 mM ammonium carbonate (solvent A) and 100 % acetonitrile 
(solvent B) as the mobile phases. The 32 min gradient HPLC run was from 80 % B to 
50 % B over 15 min, then to 5 % B at 18 min, followed by a wash with 5 % B for 3 min 
and re-equilibrated with 80 % B at a flow rate of 0.3 mL/min. Metabolite detection was 
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performed using a high-resolution Q Exactive MS (ThermoFisher) in both positive and 
negative ionisation modes. The PBQC sample was run periodically throughout each 
LC-MS batch to monitor signal reproducibility and support downstream metabolite 
identification. Extraction solvent blank samples were also analysed to identify possible 
contaminating chemical species. To aid in metabolite identification, approximately 250 
authentic metabolite standards were analysed prior to each LC-MS batch and their 
peaks and retention time manually checked using the ToxID software (ThermoFisher). 
 Metabolomics data were analysed using the IDEOM workflow (Creek et al., 
2012). Briefly, the IDEOM processing pipeline uses msconvert for conversion of raw 
files to mzXML files and split polarity, XCMS to extract raw peak intensities and 
mzMatch to align samples, filter noise, fill missing peaks and annotate related peaks. 
Manual assessment of spiked internal standards, total ion chromatograms and median 
peak heights ensured signal reproducibility and allowed exclusion of outlier samples. 
High confidence metabolite identification (MSI level 1) was made by matching 
accurate mass and retention time to authentic metabolite standards (Sumner et al., 
2007). Putative identifications (MSI level 2) for metabolites lacking standards were 
based on exact mass and predicted retention times (Creek et al., 2011). Univariate 
statistical analysis was performed using IDEOM and Welch’s t test (Creek et al., 2012). 
Multivariate statistical analysis was performed on the mean centred and auto-scaled 
data using the web-based tools, Metaboanalyst (Xia et al., 2015). Sparse partial least 
squares – discriminant analysis (sPLSDA) algorithms were run with increasing 
numbers of metabolites in each component. The final sPLSDA plots shown were 
developed using 30 metabolites in each component.  
2.5.8 Calculating drug EC50 values 
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 P. falciparum 3D7 parasites were used to calculate EC50 values. For this assay, 
50 µl of parasite culture at 0.5 % parasitemia was transferred to a U-bottom 96-well 
plate, to which 50 µl of diluted drug was added. Drugs were dissolved in DMSO and 
diluted in culture medium to achieve the following concentrations (which were within 
concentration ranges previously found in other laboratories): MIPS1700, 3200 nM - 
3.13 nM; MIPS1788, 1000 nM - 0.98 nM; MIPS2571, 14.496 µM - 14.16 nM and 
MIPS2673, 3136 nM - 3.06 nM. Controls used were parasite cultures treated with the 
highest concentration of DMSO used for each individual drug and uninfected RBCs. 
Parasites were then allowed to grow for 72 hours before the plate was placed at -80oC. 
Four independent assays were performed in triplicate.           
 The plates were removed from -80oC and the cultures allowed to thaw at room 
temperature. From each well, 50 µl was transferred to a flat-bottomed 96 well plate 
containing 50 µl of lysis buffer (20 mM Tris pH 7.5, 5 mM EDTA, 0.008 % (w/v) Saponin 
and 0.08 % (v/v) Triton X-100 in MilliQ H2O) and 0.2 µl/ml of SYBR Green I, which is 
a nucleic acid dye that binds to DNA and is representative of parasitaemia. Plates 
were incubated in the dark at room temperature for one hour. Fluorescence was then 
read on a Glomax Multiplate Luminator (Promega) at excitation and emission 
wavelengths of 485 nm and 528 nm respectively. This data was analysed using 
GraphPad Prism 7 where the EC50 was calculated. 
2.5.9 Assessment of parasite growth treated at 5 x and 10 x EC50 
 Parasites were sorbitol and heparin synchronised to allow an invasion window 
of between 0 - 4 hours. Parasites were then cultured in the presence of drug at 5 x 
and 10 x EC50 values previously calculated, or the corresponding final concentration 
of 10 x DMSO (vehicle control). Blood smears were taken every 6 hours to assess 
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growth; smears were fixed on glass slides with methanol for 10 seconds before being 
stained with Giemsa for 5 - 10 minutes. Treatments were performed over two technical 
replicates. Images were captured on SC50 5-megapixel colour camera (Olympus) at 
100 x magnification under oil magnification.  
 
2.6 Statistical analysis 
 Unless otherwise indicated, three biological replicates were performed to 
calculate statistical significance between two experimental groups using an unpaired 













Table 2.1: Oligonucleotides used in this study 
Oligonucleotide 
 
Target  Sequence (5’ to 3’) 
DO276 glmS  5’ TCCTTGAACAAAGAGAAATCAC 3’ 
DO694 T7 
 
5’ GTTGTGTGGAATTGTGAGCGG 3’  
DO657 PfM17LAP 5’ AATAACCGCGGGGATCAGTTGCTGATTTAAGT 3’  
DO658 PfM17LAP 5’ TTGTACTCAATGACGCTCTAGGGCGCGCCTTATT 3’ 
DO733 PfM17LAP 5’ GACCGATGAAAGGTTCAAATCT 3’ 
DO734 PfM17LAP 5’ CATGTGTGGTGTACCTCAC 3’ 
DO765 M13  5’ GTAAAACGACGGCCAG 3’ 
DO766 M13  5’ GTCATAGCTGTTTCCTG 3’  
DO934 PfM1AAP 5’ ACGTAACAGACTTAGGAGGAGATCTAAGAAATGATATCACAAACCAC 3’  
DO935 PfM1AAP 5’ GAATATTTATTAAGATTAACAAATAAATTAGCTGCAGCTTACCCGTACGACGTCC 3’ 
DO936 PfM1AAP 5’ CTCCACCGCGGTGGCGGCCGCATTACATAGTATGCACATGTTAATG 3’  
DO937 PfM1AAP 5’ GAAAATACTTGTTCAGATAAAAGAATGAAGAAATGAT 3’  
DO938 PfM1AAP 5’ TAAAAGAATG AAGAAATGATATCACAAACCACCT 3’  
DO939 PfM1AAP 5’ GATGAATCACATGTAGATTTTGATCTGCAGGAATTCGATATC 3’  
DO940 PfM1AAP 5’ ATTGATTCCATGACCTTCTTCAAA 3’  
DO941 PfM1AAP 5’ ATTCCATGACCTTCTTCAAAGTTT 3’  
DO942 PfM1AAP 5’ ATTGGGCTTAATTAATCCAGAAAA 3’  
DO943 PfM1AAP 5’ GGCTTAATTAATCCAGAAAAGTTT 3’  
DO945 PfM17LAP 5’ GCAAGTGAAGTACCACAAGTTGTTTCAAAGC 3’  
DO948 PfM17LAP 5’ ATTGAGGAATACTTGTTGGATCTA 3’  
DO949 PfM17LAP 5’ AGGAATACTTGTTGGATCTAGTTT 3’  
DO950 PfM17LAP 5’ ATTGTTGATATTGCTGGTGTTTCA 3’  
DO951 PfM17LAP 5’ TTGATATTGCTGGTGTTTCAGTTT 3’  
DO954 Neo glmS 5’ ACAGACTTAGGAGGAGATCT 3’  
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DO955 2A peptide 5’ CAATGATTGAACAAGATGGAT 3’  
D01027 PfM17LAP 5’ CACCGCGGTGGCGGCCGCTTAAATATTCCTTATATATTTGCTACG 3’  
DO1028 PfM17LAP 5’ GTCTATGTATCACTATTCAATATTGCTGCAGGAATTCGATATCAAG 3’  
DO1061 PfM17LAP 5’ GGCAAGTGAAGTACCACAAGTTGTTTCAAAGCTAGAAAAC 3’  
DO1085 PfM1AAP 5’ GCAGACAATTCAGCTAACCTAAACC 3’ 
DO1118 PfM17LAP 5’ CGGCCTTTGTATGTGTGACGTTTG 3’  
DO1119 PfM17LAP 5’ GGCAAGTGAAGTACCACAAGTTG 3’  
DO1120 PfM1AAP 5’ GTACACACACAATAAGGATGGATTC 3’  
DO1166 PfM17LAP 5’ GTGCATAATACATAAGAAGATTTTATTTG 3’  
DO1244 PfM17LAP 5’ CCTAAAATCTACTATACACAGTGG 3’  













Table 2.2: Plasmids used in this study 
Plasmid Description 
pPf-Sortilin-HA-glmS Starting plasmid for creation of PfM1AAP tagged line 
pPTEX150-HA-2A-Neo-glmS Starting plasmid for creation of PfM1AAP tagged line (Burnet 
Institute) 
pdc2-CAM-Cas9-U6-hDHFR Starting plasmid for creating Cas9 targeted plasmids (Dr Marcus 
Lee, Sanger Institue) 




Targeted plasmid for deletion of PfM1AAP 
pdc2-CAM-Cas9-U6-M1guide2-
hDHFR 
Targeted plasmid for deletion of PfM1AAP 
pdc2-CAM-Cas9-U6-M17guide1-
hDHFR 
Targeted plasmid for deletion of PfM7LAP 
pdc2-CAM-Cas9-U6-M17guide2-
hDHFR 
Targeted plasmid for deletion of PfM17LAP 
pPf-M1-HA-glmS Plasmid for creation of PfM1AAP HA-tagged riboswitch line 
pBSKS-M1-HB Plasmid containing homology boxes for PfM1AAP knockout 
parasite lines 





Table 2.3: Primary antibodies used in the study 





Anti-HA Mouse 1:1000 1:250 Life Technologies 
Anti-EXP2 Rabbit 1:2000 N/A (Bullen et al., 
2012) 
Anti-MSP1 Rabbit N/A 1:500 (de Koning-Ward 
et al., 2003) 





















Characterising the effect of knockdown and 











3.1  Introduction 
The majority of our current knowledge surrounding the function of M17 in 
Plasmodium is based on kinetic studies performed on the enzyme expressed and 
purified from the bacterium E.coli (Drinkwater et al., 2018; Stack et al., 2007; Thivierge 
et al., 2012). While this gives a thorough understanding of its structure, binding 
affinities and preferential environment, it only provides limited insight into its function 
within its natural context, that being the parasite. Other studies have focussed on 
targeting this protein in P. falciparum cultured in vitro with known or novel inhibitors to 
infer M17 function (Abu Bakar et al., 2010; Gardiner et al., 2009; Harbut et al., 2011), 
but off-target effects cannot be definitively ruled out without prior characterisation of 
the importance of the enzyme at the biological level. 
To date, studies performed to elucidate the essentiality of M17 have only been 
performed in the rodent species P. berghei, where it was shown to be dispensable for 
blood-stage growth in vivo (Lin et al., 2015). Recently, high-throughput piggyBac 
transposon insertional mutagenesis has been performed in the human species P. 
falciparum (Zhang et al., 2018). Since transposons failed to insert into the Pfa-m17 
gene locus, this suggests that conversely to P. berghei, this gene is likely to be 
essential in P. falciparum. These findings are also consistent with previous failed 
attempts in P. falciparum to knockout this gene using conventional transfection 
approaches (Dalal and Klemba, 2007). Nevertheless, it should be noted that failure to 
knockout a gene in P. falciparum is not necessarily indicative of essentiality given the 
poor transfection efficiency of this species and reliance on spontaneous breaks in the 
genome to facilitate homologous recombination.  
52 
 
This chapter aims to characterise the essentiality of the PfA-M17 enzyme by 
attempting to delete a portion of gene encoding the enzyme using the robust CRISPR-
Cas9 system. Conditional knockdown of Pfa-m17 at the mRNA level using the 
riboswitch method additionally aims to develop an understanding of the function of 
PfA-M17 by studying the phenotypic response of the parasite after depletion of this 
enzyme.   
 
3.2 Results 
3.2.1 Generation of a transgenic PfA-M17 tagged parasite line  
 The generation of a transgenic P. falciparum line in which PfA-M17 was epitope 
tagged at its C-terminal end with a triple hemagglutinin (HA) and a single strep II (Str) 
epitope tag was performed by Kathryn Hjerrild, a previous researcher in the laboratory. 
A pM17-HAglmS targeting construct was created (Figure 3.1) that contained the last 
1.2 kB of the PfA-M17 gene (PF3D7_1446200) (Aurrecoechea et al., 2009) minus the 
stop codon, followed by sequences encoding the epitope tags and a 3’ UTR containing 
a glucosamine-inducing glmS ribozyme. The plasmid also incorporated a human 
dihyrdrofolate reductase (hDHFR) expression cassette that encodes resistance to the 
drug WR99210. This construct was transfected into synchronised ring-stage P. 
falciparum 3D7 parasites and cultures were maintained until parasites were detected 
by microscopy. Parasites surviving WR99210 drug pressure underwent rounds of drug 
cycling, whereby drug pressure was removed for three weeks and then re-applied, to 
eliminate parasites that were replicating the plasmid episomally and to select for 
integrants. The resulting transgenic parasite line was termed PfM17-HAglmS. To 













Figure 3.1: Targeting construct for generation of the PfM17-HAglmS line 
Targeting construct used to generate the PfA-M17 riboswitch parasite line. The targeting 
construct consists of the last 1.2 kb of the Pfa-m17 locus, a triple hemagglutinin (HA) and 
single strep II (Str) epitope tag, a glmS ribozyme within a synthetic 3’ untranslated region 
(UTR) and the human dihydrofolate reductase (hDHFR) expression cassette that encodes 
resistance to the drug WR99210. The locus after the expected integration event is shown. 
Oligonucleotides used to confirm integration are shown with expected sizes after PCR 







by limiting dilution, giving rise to the clonal line 2E7. All subsequent work on this 
parasite line was performed by myself. 
3.2.2 Confirmation of the PfM17-HAglmS parasite line 2E7 
The parasite line 2E7 was produced via serial dilution cloning of the PfM17-
HAglmS parental line. Oligonucleotides were designed to confirm integration of the 
pM17-HAglmS targeting construct into the Pfa-m17 locus by PCR. Genomic DNA was 
prepared from both parental 3D7 wildtype (WT) parasites as well as from the PfM17-
HAglmS parasite line 2E7 for analysis. PCR was performed using the oligonucleotides 
outlined in Figure 3.1. As expected, oligonucleotides DO657 and DO658, which were 
used to generate the Pfa-m17 fragment inserted into the pM17-HAglmS targeting 
construct, amplified a fragment from both WT and the 2E7 clone. DO733 (which binds 
to a region upstream of the expected integration site) and DO276 (which binds to a 
region within the HA tag sequence) only yielded a PCR product from genomic DNA 
isolated from clone 2E7 and not WT parasites, indicating that integration of the 
targeting construct had occurred (Figure 3.2). DO733, when used in conjunction with 
DO734 (which binds to a sequence within the endogenous 3’UTR), only produced a 
PCR product from WT template and thus the absence of this product from 2E7 
confirms that this line is indeed clonal (Figure 3.2).  
After integration of the targeting construct into the Pfa-m17 locus was confirmed by 
PCR, it was important to check that the parasite line was correctly expressing PfA-
M17. To do this, asynchronous cultures of the WT and 2E7 parasite lines were saponin 
lysed to extract protein before undergoing Western blotting; membranes were probed 
with a mouse anti-HA antibody. A protein band at a slightly smaller mass than 
















Figure 3.2 PCR confirmation that the pM17-HAglmS targeting construct has integrated 
into the Pfa-m17 locus 
Oligonucleotides outlined in Figure 3.1 were used on both parental (wildtype, WT) 3D7 and 
PfM17-HAglmS clone 2E7 to confirm integration of the pM17-HAglmS construct. Expected 























Figure 3.3 Western blot confirming HA-tagging of PfA-M17 in clone 2E7 
Western blots of P. falciparum parental wildtype (WT) and PfM17-HAglmS 2E7 parasite lines 
were probed with either mouse anti-HA antibody or rabbit anti-HSP70 (loading control). 
Expected molecular masses for PfA-M17 containing the HA and Strep epitope tags and 


















Figure 3.4 Immunofluorecence analysis of the parasite line 2E7 
Immunofluorecent analysis performed on red blood cells (RBCs) infected with the PfM17-
HAglmS parasite line 2E7 at different stages of the parasite lifecycle. RBCs were fixed with 
acetone/methanol and anti-HA antibodies were used to probe for PfA-M17. Other proteins 
labelled are merozoite surface protein 1 (MSP1, red), which after merozoite invasion localises 






the result of protein processing (naturally or during saponin lysis) or that the charge of 
the protein affects the mobility on the gel (Figure 3.3). Importantly, the band was 
absent from the WT sample. These results indicate that the clonal PfM17-HAglmS line 
2E7 has integrated the pM17-HAglmS targeting construct and is correctly expressing 
the HA-tagged M17 protein. Probing with a monoclonal rabbit anti-HSP70 antibody 
was used to confirm similar amounts of protein had been loaded for each sample. 
Immunofluorescence analysis (IFA) was performed on erythrocytes infected 
with the 2E7 line, where labelling with anti-HA antibodies again confirmed the 
expression of the epitope-tagged PfA-M17 (Figure 3.4). The protein did not appear to 
co-localise with merozoite surface protein 1 (MSP1), which localises to the food 
vacuole after merozoite reinvasion and prior to schizogony, or with the nucleus 
(labelled with DAPI). This supports previous findings of PfA-M17 being a cytoplasmic 
protein that is excluded from the food vacuole (Thivierge et al., 2012).      
3.2.3 Analysis of PfA-M17 expression over the parasite erythrocytic cycle 
Epitope tagging of PfA-M17 allows analysis of the protein over the different 
developmental blood stages of the parasite via probing with an anti-HA antibody. 
Parasites were double sorbitol synchronised and saponin-lysed at different time points 
post reinvasion to represent the ring, early trophozoite (ET), late trophozoite (LT) and 
schizont stages of the parasite erythrocytic cycle. Protein lysates underwent Western 
blotting, with the membrane probed with a mouse anti-HA antibody. Consistent 
expression levels could be seen throughout the ring, ET and LT stages, with an 
increased expression level seen at schizogony (Figure 3.5). HSP70, which is also 


















Figure 3.5 Expression of PfA-M17 over the erythrocytic cycle of P. falciparum 
Western blots of protein lysates from various stages of the P. falciparum erythrocytic cycle 
were probed with mouse anti-HA antibody and rabbit anti-HSP70 (loading control). Expected 
sizes are 71kDa and 70kDa for PfM17-HAglmS and HSP70, respectively. ET early 



















Figure 3.6 Expression analysis of PfA-M17 in three different P. falciparum strains 
RNA microarray was used to examine the expression of PfA-M17 (PF3D7_1446200) across 
48 individual 1-h time points from the intra-erythrocytic development cycle of P. falciparum 
strains 3D7, Dd2 and HB3. Transcription peaks at the late schizont/early ring-stage. Graph 






was detected with a rabbit monoclonal antibody and showed a similar expression 
pattern. Analysis of the transcriptional profile of Pfa-m17 taken from PlasmoDB 
(Aurrecoechea et al., 2009) shows that there is a continuous increase in transcription 
from approximately 30 hours onwards in the parasite line 3D7, with peaks in late 
schizogony and early rings in the following cycle (Figure 3.6). Therefore, the protein 
may already be made in schizonts, where it may be carried into the next cycle by the 
invading merozoite and additional protein may also be expressed following invasion. 
As the expression of PfA-M17 appears to be stable throughout the cycle with little 
protein turnover, PfA-M17 may function throughout the entirety of the parasite 
erythrocytic cycle.   
3.2.4 PfA-M17 expression can be regulated by the addition of glucosamine 
 In transgenic parasite lines in which the artificial ribozyme, termed riboswitch, 
has been inserted into the 3’ UTR of a genomic locus, the addition of 2.5 mM 
glucosamine (GlcN) to parasite cultures is sufficient to activate the ribozyme, leading 
to cleavage of the mRNA. Thus, to determine whether PfA-M17 can be conditionally 
regulated with GlcN, Western blot analysis was performed on protein extracted from 
trophozoite stages of synchronised 2E7 grown in culture in the presence (+) or 
absence (-) of 2.5 mM GlcN, added at the ring stage of the lifecycle, for either one or 
two cycles. Membranes were probed with mouse anti-HA antibodies, as well as 
rabbit anti-HSP70 (loading control). This revealed that HA-tagged PfA-M17 protein 
levels could be significantly depleted with GlcN, even during cycle 1. Three 
independent biological experiments revealed an average knockdown of protein of 
84% and 92% for cycle 1 and 2, respectively, relative to protein levels in parasites 


















Figure 3.7 Protein regulation of HA-tagged M17 after addition of glucosamine 
(A) Synchronised 2E7 parasites either treated with (+) or without (-) 2.5 mM glucosamine 
(GlcN) were saponin lysed at trophozoite stage in cycle 1 (C1) or cycle 2 (C2). Representative 
Western blot of protein pellets that were probed with mouse anti-HA antibody and rabbit anti-
EXP2 (loading control). (B) Densitometry performed on bands observed in Western blot was 
performed using ImageJ software. The ratio of protein expression in GlcN-treated parasites 
relative to EXP2 (loading control) was compared to that of untreated parasites. Significant 
reduction of HA-tagged PfA-M17 was seen in both C1 and C2. Shown is the mean +/- standard 
deviation (n= three biological experiments). Statistical significance was determined using an 




3.2.5  Knockdown of PfA-M17 results in growth arrest and parasite death 
 Once it could be demonstrated that PfA-M17 expression could be conditionally 
depleted using GlcN, the effect of this knockdown on the parasite could be determined. 
Previously it has been shown that 2.5 mM GlcN does not substantially affect normal 
parasite proliferation and growth of wildtype 3D7 P. falciparum parasites or transgenic 
parasites lacking the riboswitch sequence (Counihan et al., 2017). Thus experiments 
were carried out on the parasite line 2E7 treated with 2.5 mM GlcN compared to 
untreated 2E7 parasites. 
To first assess the effect of inducibly knocking down the expression of PfA-M17 
on parasite growth, 2E7 parasites were sorbitol synchronised twice within 12 hours, 
creating a tightly synchronised parasite population. After the second sorbitol 
synchronisation, GlcN was added at the ring stage and smears of the culture were 
taken approximately every 6 hours. Percent parasitemias were calculated by counting 
the number of infected RBCs present in 1000 cells, with Figure 3.8 representing the 
results from three independent biological experiments. No significant difference was 
seen in parasitemias of parasites cultured in the presence or absence of GlcN during 
cycle 1, most likely because protein knockdown is not complete as some transcript 
and protein had already been synthesized by the time GlcN had been added in the 
first cycle, with this remaining protein sufficient for enzymatic activity. There was also 
no significant difference in the parasitemia in the following cycle (cycle 2) however 
there was a stalling of parasite development from the trophozoite stage of parasites 
cultured in GlcN in cycle 2, however these cultures were not analysed further to see if 
they could progress into cycle 3. To further investigate how altering the timing of PfA-
M17 knockdown impacted on parasite development, parasites were synchronised to 









   
 
 
Figure 3.8 Percent parasitemias of sorbitol-synchronised 2E7 cultures grown in the 
presence or absence of glucosamine over two parasite life cycles  
(A) Sorbitol-synchronised parasites at ~10 hrs post-invasion were either treated (2.5mM) or 
untreated (0mM) with glucosamine (GlcN) for 2 cycles (as indicated by C1-C2). 
Representative Giemsa-stained smears at the indicated hours post-invasion indicate time-
points at which parasitemias were counted. (B) Smears of 2E7 parasites either treated or 
untreated with GlcN were taken at time points indicated in (A). Shown is the mean % 
parasitema +/- standard deviation (n= three biological experiments). No significance difference 




Figure 3.9 Representative Giemsa-stained parasite smears of 2E7 cultures grown in the 
presence or absence of glucosamine 
Cultures of heparin-synchronised parasites at 4 hrs post-invasion were either treated (2.5mM) 
or untreated (0mM) with glucosamine (GlcN) for up to 4 cycles (as indicated by C1-C4). 
Representative Giemsa-stained smears at the indicated hour’s post-invasion time-points show 
parasites treated with GlcN stalling at cycle 2, with only a small subset of parasites in the 


















Figure 3.10 Percent parasitemia of heparin-synchronised 2E7 cultures grown in the 
presence or absence of glucosamine over four parasite life cycles  
Percent parasitemia of heparin-synchronised 2E7 parasites either treated (2.5 mM) or 
untreated (0 mM) with glucosamine (GlcN). When cultures grown in the absence of GlcN 
reached trophozoite stage, smears were made to determine the parasitemia. Shown is the % 






was removed for four hours to allow re-invasion, after which a sorbitol synchronisation 
was performed to lyse any remaining schizonts, ensuring that all parasites were 
between 0 - 4 hours old. Cultures were then immediately treated with 2.5 mM GlcN or 
left untreated and smears taken every 6 hours. There were no differences in parasite 
growth between the treated and untreated cultures in cycle 1, however, there was a 
severe delay in parasite development within cycle 2, as well as parasite death (Figure 
3.9 and Figure 3.10). It is important to note that haemozoin crystal can clearly be seen 
within parasites in cultures treated with GlcN when fixed onto slides and Giemsa-
stained; this indicates that at least the earliest stages of haemoglobin digestion had 
already occurred. Only a small subset of parasites eventually made it to schizogony 
and reinvaded new RBCs (cycle 3), but the time this cycle 3 commenced the untreated 
parasite group had already commenced cycle 4 (Figure 3.9). That some parasites 
made it through to cycle 3 is probably due to residual levels of PfA-M17 expression as 
a result of incomplete cleavage of the riboswitch after addition of GlcN to culture.  
3.2.6 Generation of constructs for CRISPR-Cas9 knockout of the Pfa-m17 locus 
Considering the severe phenotype that was seen after knockdown of PfA-M17, 
knockout of the gene was also attempted using the CRISPR-Cas9 method to confirm 
that the protein is essential, as described in previous literature (Dalal and Klemba, 
2007). The plasmid containing the Cas9 nuclease was kindly supplied by Dr Marcus 
Lee from the Sanger Institute. Guide sequences were identified using the Benchling 
program (https://benchling.com/crispr), based on their location immediately upstream 
of an ‘NGG’ sequence, and each were 20 base pairs in length. The guides designed 
to direct the Cas9 nuclease to knockout a portion of the Pfa-m17 locus were located 





Figure 3.11 Targeting constructs for generation of PfA-M17 knockout parasites using 
CRISPR-Cas9 
The CRISPR-Cas9 construct contains the gene encoding the Cas9 nuclease, a guide RNA 
sequence and the hDHFR selectable marker. Stars represent the two separate guide 
sequence locations. The donor plasmid contains two homology box boxes (HBs) on a 
bluescript (pBSKS) backbone that serve to repair the Pfa-m17 locus by homologous 
recombination. The locus before and after deletion are shown, and the oligonucleotides used 
to amplify the homology box sequences, as well as to test for integration, are indicated.   
69 
 
stop codon (Guide 2) (Figure 3.11). Each of these guides were cloned into the BbsI 
site of the pM17-Cas9-Guide1/2 vector. Two guides were chosen to increase the 
likelihood of success using this system. Since the breaks in the DNA created by the 
Cas9 nuclease can only be repaired by homologous recombination, the plasmid pBS-
M17HB was created, which contains two Pfa-m17 homology boxes of ~600 bp in 
length. These homology boxes were amplified using P. falciparum 3D7 genomic DNA 
as a template and HIFI cloned into the NotI and PstI sites of the bluescript plasmid 
(pBSKS). pBS-M17HB was co-transfected alongside the Cas9 nuclease plasmid 
containing one of the two guides into P. falciparum 3D7 wildtype parasites. These 
transfections were performed on up to four separate occasions. Successful repair of 
the Cas9-cleaved site in the Pfa-m17 locus using these homology boxes is expected 
to create a deletion of 1510 bp of coding sequence, leading to a non-functional, 
truncated protein of ~12.5 kDa protein lacking the aminopeptidase active site. 
3.2.7 PCR confirmation of deletion of the Pfa-m17 locus 
Parasites transfected with pBS-M17HB alongside pM17-Cas9-Guide1 or 2 
were recovered ~18 days after transfection. Genomic DNA was extracted from 
parasites transfected with either guide number 1 (M17G1) or with guide number 2 
(M17G2). Oligonucleotides outlined in Figure 3.11 were used to perform PCR analysis 
to discern if the Pfa-m17 locus had been successfully targeted for deletion in the 
parasite lines (herein named M17G1 and M17G2) (Figure 3.12). DO1118 and DO1119 
encode sequences within homology box 1 or 2, respectively, resulting in a much 
smaller fragment if sequences in between the homology boxes are deleted. A smaller 
fragment was clearly evident for M17G1 PCR, with no wild type band present. M17G2 
produced a strong band for the wild type locus, but a faint band indicative of deletion 
















Figure 3.12 PCR analysis of parasites after transfection with PfA-M17 knockout 
CRISPR-Cas9 plasmids 
Genomic DNA was extracted from parental 3D7 wildtype (WT) parasites recovered after 
transfection with pBS-M17HB alongside one of pM17-Cas9-Guide1/2. Oligonucleotides 







oligonucleotides DO1027 and DO1118, a band indicative of deletion of Pfa-m17 is 
evident for both M17G1 and M17G2, but again for the latter, a band representing a 
wildtype locus is also present; this suggests that a sub-population of this parasite line 
may have the knockout locus, while there is still a wild type population present. 
Oligonucleotides used to PCR amplify the first homology box, located at the 5’UTR 
end of the gene, was used as a control, and as expected, generated products for both 
wildtype and transgenic parasite lines. That transgenic parasites could survive with a 
region of the Pfa-m17 gene being deleted after being in culture for more than several 
weeks was surprising, given that knockdown of PfA-M17 expression led to a severe 
phenotype after only a few cycles in culture.  
3.2.8 Generation of a clonal population of Pfa-m17 knockout parasites 
 To ensure that the population of parasites containing the knockout Pfa-m17 
locus was pure and did not harbour any wildtype parasites that could impact on 
downstream analysis and interpretations, the M17G1 and M17G2 lines underwent 
limiting-dilution cloning. Intriguingly, clonal populations could never be recovered from 
serial dilution cloning of the parental M17G1 line, but clones were initially recovered 
for the M17G2 parental line. To determine whether these resulting parasite 
populations were indeed clonal, genomic DNA was extracted from three individual 
clones. The same PCR reactions described in Section 3.2.7 were performed, with all 
three clones (1C2, 3C2 and 8G2) of M17G2 positive for deletion of the Pfa-m17 
genetic locus by PCR (Figure 3.13). Further analysis on the clonal population is 
required to validate that the truncated protein is the form present in these parasites, 
as well as transcriptional analysis to determine if deletion of part of the Pfa-m17 gene 


















Figure 3.13 PCR analysis of parasites cloned out from M17G2 parental line 
Parasites were cloned out by limiting dilution of the parental line M17G2. Genomic DNA 
extracted from parental wildtype (WT) parasites and three clones were analysed by PCR using 
oligonucleotides outlined in Figure 3.11. All three clones (1C2, 3C2, 8G2) were shown to be 







3.3  Discussion 
There has been extensive work undertaken to develop inhibitors against the 
M17 enzyme in Plasmodium, but there is limited knowledge about its function and 
essentiality within the parasite. The generation of a PfM17-HAglmS line outlined in this 
study not only allows characterisation of the epitope-tagged protein, but it also allows 
knockdown of the enzyme at the mRNA level for phenotypic analysis to allow further 
understanding of its function and essentiality. Without this knowledge the potential of 
this aminopeptidase as a drug target cannot be fully understood.    
The addition of 2.5 mM GlcN on double sorbitol-synchronised parasites did not 
produce any significant difference in percent parasitemias relative to parasites grown 
in the absence of GlcN, most likely because some protein may have already been 
made the cycle before and been carried over in the invading merozoite. Cleavage of 
the mRNA through the addition of GlcN was also not 100% and so any residual 
enzyme may perhaps be sufficient for function and thus parasites could complete the 
cycle and reinvade new erythrocytes. These experiments gave some insight into the 
phenotype resulting from knocking down PfA-M17, as GlcN-treated lines exhibited an 
obvious stalling of the parasite lifecycle at the early trophozoite stage in the cycle 
following GlcN addition (Cycle 2). Despite the fact that initial knockdown experiments 
were performed on double sorbitol synchronised parasites, it should be noted that the 
window in the age of parasites can be between 8 - 12 hrs. Heparin synchronised 
parasites were thus used to further analyse the protein knockdown, with the addition 
of GlcN to 0 - 4 hour old 2E7 rings giving consistent results with the previous 
knockdown experiments. Parasites proceeded through cycle 1 before stalling at the 
trophozoite stage in cycle 2, with haemozoin still seen in knockdown parasites as 
expected, with the formation of this crystal occurring before PfA-M17 becomes 
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involved in haemoglobin digestion. Whilst a small subset of parasites did complete 
cycle 2 and proceeded to reinvade new RBCs and commence cycle 3, the parasites 
were almost a whole cycle behind the untreated parasites. The ability of some 
parasites to survive may be due to the incomplete knockdown of PfA-M17 (92% 
knockdown in cycle 2 parasites as determined by Western blot).  
Given such a severe phenotype after knockdown of PfA-M17, it was surprising 
to have parasites recover after being transfected with the CRISPR-Cas9 knockout 
constructs. Parasites could be recovered after two separate guide sequences were 
transfected on two separate occasions. Dilution cloning on both the M17G1 and 
M17G2 populations was performed to ensure the populations were pure. However, for 
M17G1, which appeared to exhibit only the knockout genotype by PCR following 
transfection, no parasites could ever be recovered after dilution cloning. For M17G2 
parasites, the transfectant population consisted of wildtype and knockout genotypes 
and although clones could be recovered that exhibited the knockout genotype by PCR, 
they became contaminated with other parasites and required additional cloning, from 
which parasites with a knockout genotype could ever be recovered. Combined these 
experiments suggest that the Pfa-m17 gene locus can be deleted but it likely comes 
at a fitness cost to the parasite, such that small numbers of wildtype parasites present 
at sub-PCR detection levels could outgrow them.    
Further analysis of the non-clonal M17G1 and M17G2 will be required to 
confirm that the Pfa-m17 locus has in fact been truncated. It is possible that genetic 
recombination of the homology boxes may have been incomplete, and the plasmid 
may have inserted after the coding sequence of PfA-M17; this would explain PCR 
bands for both wildtype and knockout parasites in the uncloned M17G2 population, 
but it cannot explain the apparent clonal populations of PfA-M17 knockout parasites. 
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To be certain that correct recombination had occurred, either sequencing or Southern 
blot analysis of genomic DNA is required. Western blot analysis can also be used to 
determine whether full-length or truncated PfA-M17 is expressed, with the generation 
of rabbit polyclonal PfA-M17 antibodies currently underway.  
If the genetic deletion of PfA-M17 has occurred as designed and a truncated 
protein is generated in the parasites, it will not contain the active site. Thus the 
truncated product will not have enzymatic function. It is possible that the transgenic 
populations could survive because they have increased the activity of other 
aminopeptidases, thus compensating for the loss of PfA-M17; this may not be evident 
after protein knockdown over 3 cycles, explaining why a lethal phenotype was seen 
with GlcN treatment. As PfA-M1 is able to cleave the subset of amino acids cleaved 
by PfA-M17, quantitative reverse transcription PCR (qRT-PCR) should be used to 
examine the levels of PfA-M1 expression in M17G1 and M17G2 parasites.  Thus in 
conclusion, while further experimentation is required to confirm that PfA-M17 can be 
knocked out, the difficulties in recovering clonal populations of knockout parasites and 
the results from the knockdown experiments indicates deletion of the protein comes 



















Development of PfA-M1 knockout and knockdown  










4.1  Introduction 
 Like PfA-M17, most of the literature surrounding PfA-M1 focuses on drug 
development and dissection of enzymatic activity in vitro (Bounaadja et al., 2017; 
Harbut et al., 2011; Velmourougane et al., 2011). A number of drugs developed to 
target the M1 aminopeptidase have been tested and so far have been shown to be 
effective at killing P. falciparum and other Plasmodium species (Harbut et al., 2011; 
Velmourougane et al., 2011); however, without knowing the function of the enzyme it 
is hard to validate whether these drugs are killing in an M1-specific manner. Similarly 
to PfA-M17, essentiality of PfA-M1 has been gleaned via untargeted high-throughput 
piggyBac transposon insertional mutagenesis (Zhang et al., 2018) and using 
conventional gene knockout approaches (Dalal and Klemba, 2007); both studies 
suggest that PfA-M1 is essential to blood-stage development of P. falciparum. 
 A Plasmodium-specific enzyme that is essential for parasite survival is an ideal 
anti-malaria target and thus it is important to validate that PfA-M1 indeed plays a 
critical role in the parasite erythrocytic cycle using targeted and more robust 
transfection tools. Further molecular analysis of PfA-M1 is also required to determine 
how PfA-M1 contributes to parasite survival. This chapter aims to use the robust 
CRISPR-Cas9 system to attempt to delete part of the genetic locus of Pfa-m1, as well 
as to develop a riboswitch and epitope-tagged line in order to assess gene function 







4.2  Results 
4.2.1 Generation of constructs for CRISPR-Cas9 knockout of the Pfa-m1 locus 
 In order to confirm the essentiality of PfA-M1, attempts were made to delete the 
genetic locus using a more robust method, CRISPR-Cas9, than previously described 
(Dalal and Klemba, 2007). The PfA-M1 CRISPR-Cas9 constructs were designed using 
the same approach used to create the PfA-M17 constructs. Briefly, two different guide 
sequences to direct the Cas9 nuclease where to make the DNA break were designed 
for PfA-M1, one that is homologous to a region 440 bases downstream of the start 
codon (Guide 1) and the other 1154 bases upstream of the end of the gene (Guide 2) 
(Figure 4.1). Each of these guides were cloned into the BbsI site of the vector pM1-
Cas9-Guide1/2 and two guides were used to increase the likelihood of obtaining a 
gene knockout. The DNA breaks caused by the Cas9 nuclease can only be repaired 
through homologous recombination, so another construct, pBS-M1HB, was created 
which provide the homology regions for repair. Two Pfa-m1 homology boxes of ~600 
bp in length were amplified using P. falciparum 3D7 genomic DNA as a template; these 
were cloned into pBSKS at the NotI and PstI sites via HIFI cloning. pBS-M1HB was 
co-transfected alongside either pM1-Cas9-Guide1 or 2, the Cas9 nuclease plasmid 
containing one of the two guides. Repair of the P. falciparum Pfa-m1 locus using these 
homology regions is expected to create a deletion of 1719 bp of coding sequence, 
leading to a non-functional truncated protein of ~17.12 kDa protein lacking the 
aminopeptidase active site (Figure 4.1).  
4.2.2 PfA-M1 is refractory to genetic deletion using CRISPR-Cas9 
 The pM1-Cas9-Guide 1 and pBS-M1HB constructs were co-transfected into P. 






Figure 4.1 Targeting constructs for generation of PfA-M1 knockout parasites using 
CRISPR-Cas9 
The CRISPR-Cas9 construct contains the gene encoding the Cas9 nuclease, a guide RNA 
sequence and the hDHFR selectable marker. Stars represent the two separate guide 
sequence locations. The donor plasmid contains two homology boxes (HBs) on a bluescript 
(pBSKS) backbone that serve to repair the Pfa-m1 locus by homologous recombination. The 
locus before and after deletion is shown, and the oligonucleotides used to amplify the 
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that was lost at day 14 due to contamination, the remaining three transfections were 
cultured for an extended period of time (31, 38 and 46 days) without any parasites 
being recovered. The pM1-Cas9-Guide 2 and pBS-M1HB constructs were co-
transfected on three separate occasions and no parasites could be detected in the 
cultures after extended periods of culturing (41, 38 and 50 days). Transfection 
attempts are summarised in Table 4.1. In contrast, when pP47-Cas9-Guide and pBS-
P47HB plasmids were co-transfected into P. falciparum 3D7, parasites in which the 
Pf-p47 locus (PF3D7_1346800) (Aurrecoechea et al., 2009) had been successfully 
knocked out (as determined by PCR) were recovered after ~24 days of culturing (data 
not shown). This indicates that the Pfa-m1 genetic locus is refractory to genetic 
deletion, suggesting that it is essential for survival in the blood stages of the P. 
falciparum lifecycle.  
4.2.3 Generation of a transgenic PfA-M1 tagged parasite line 
 As PfA-M1 was refractory to genetic deletion, the development of a riboswitch 
line which tags the protein will allow analysis of localisation and expression, as well as 
determining function by phenotypic analysis after protein knockdown. The same 
plasmid sequence was used to construct the PfM1-HAglmS tagged parasite line as 
was used to develop the PfM17-HAglmS tagged parasite line, with the pM1-HAglmS 
construct containing the last 1.2 kilobases of the Pfa-m1 gene (PF3D7_1311800) 
(Aurrecoechea et al., 2009) minus the stop codon serving as the targeting sequence. 
The Pfa-m1 sequence was PCR amplified from parental wildtype (WT) 3D7 genomic 
DNA and cloned upstream of the triple hemagglutinin (HA) and single strep II (Str) 
epitope tags into the PfSortilin-HAglmS plasmid (Hallée et al., 2018) using the Gibson 












Figure 4.2: Targeting construct for generation of the PfM1-HAglmS line 
Targeting construct used to generate the PfA-M1 riboswitch parasite line. The targeting 
construct consists of the last 1.2 kb of the Pfa-m1 locus, a triple hemagglutinin (HA) and single 
strep II (Str) epitope tag, a glmS ribozyme within a synthetic 3’ untranslated region (UTR) and 
the human dihydrofolate reductase (hDHFR) expression cassette that encodes resistance to 
the drug WR99210. The locus after the expected integration event is shown. Oligonucleotides 






in the 3’UTR. It also contains a human dihydrofolate reductase (hDHFR) expression 
cassette that encodes resistance to the drug WR99210 (Figure 4.2).  
 The pM1-HAglmS targeting construct was transfected into synchronous ring-
stage P. falciparum 3D7 parasites and cultured until parasites were detectable by 
microscopy. At this point, parasites underwent drug cycling whereby WR99210 drug 
pressure was removed for three weeks and then reapplied to ensure the loss of pM1-
HAglmS episomes and the selection of parasites containing integrated plasmid, 
respectively. The resulting parasite line was termed PfM1-HAglmS.   
4.2.4 Confirmation of construct integration into the PfM1-HAglmS parasite line 
 After three rounds of drug cycling, genomic DNA was extracted from the PfM1-
HAglmS line and analysed by PCR to determine whether integration of the pM1-
HAglmS targeting construct had occurred. Genomic DNA was prepared from both 
parental 3D7 (WT) and PfM1-HAglmS parasite lines for analysis. PCR was performed 
using the oligonucleotides outlined in Figure 4.1. A band consistent with integration of 
the HA tag was seen using oligonucleotides DO1085 and DO276, however a band 
indicative of the presence of WT parasites could also be seen from the oligonucleotide 
combination DO1085 and DO1120 (Figure 4.3A). This indicated that the parasite line 
was not clonal for integrants and thus the parasite line underwent a further round of 
drug cycling (cycle four), where this WT band disappeared when analysed by PCR 
(Figure 4.3B); however, the WT band re-appeared in populations produced from serial 
dilution cloning of this parental line. Oligonucleotides DO934 and DO935, which 
amplify the Pfa-m1 targeting sequence was used as a control throughout. 
 Asynchronous PfM1-HAglmS parasites that had undergone four rounds of drug 










Figure 4.3 PCR confirmation that the pM1-HAglmS targeting construct has integrated 
into the Pfa-m1 locus after drug cycling 
Oligonucleotides outlined in Figure 4.1 were used on both parental (wildtype, WT) 3D7 and 
PfM1-HAglmS lines to confirm integration of the pM1-HAglmS construct after three (A) or four 















Figure 4.4 Western blot confirming HA-tagging of PfA-M1 after four rounds of drug 
cycling 
Western blots of P. falciparum parental wildtype (WT) and PfM1-HAglmS parasite lines were 
probed with either mouse anti-HA antibody or rabbit anti-HSP70 (loading control). Expected 
molecular masses for PfA-M1 containing the HA and Strep epitope tags and HSP70 are 128 















Figure 4.5 Immunofluorescence analysis of the parasite line PfM1-HAglmS 
Immunofluorescent analysis performed on red blood cells (RBCs) infected with PfM1-HAglmS 
after four rounds of drug cycling. RBCs were fixed with acetone/methonal and anti-HA 
antibodies were used to probe for PfA-M1. Other proteins labelled are merozoite surface 





parasites, to ensure correct expression of the tagged Pfa-m1 locus. Membranes were 
probed with mouse anti-HA antibodies, which showed a protein band of equivalent 
molecular mass to that expected for epitope tagged PfA-M1 (128 kDa). This band was 
absent from the WT sample, confirming that the PfM1-HAglmS transgenic parasite line 
was correctly expressing the tagged protein (Figure 4.4). The membrane was also 
probed with a monoclonal rabbit anti-HSP70 antibody as a loading control.    
 Immunofluorescence analysis (IFA) performed on RBCs that were infected with 
PfM1-HAglmS line and labelled with mouse anti-HA antibodies again confirmed the 
expression of the epitope tagged PfA-M1. Similarly to PfA-M17HA, PfA-M1HA, did not 
appear to co-localise with merozoite surface protein 1 (MSP1) or with the nucleus 
(indicated by DAPI staining) but instead indicated that the protein is locating to the 
parasite cytoplasm (Figure 4.5).   
 While the Western blot and IFA shows a population of P. falciparum parasites 
have integrated the pM1-HAglmS targeting construct into the correct genetic locus, 
clonal populations of parasites have yet to be generated. Numerous attempts have 
been made to generate a clonal population of PfM1-HAglmS parasites which have 
either undergone three or four rounds of drug cycling via serial dilution. However, in 
each case PCR analysis of apparent clonal parasites has confirmed the presence of 
WT parasites (as seen in Figure 4.2A, data not shown), even parasites after cycle four, 
in which no WT parasites could be detected prior to cloning. To validate the amplified 
product generated from oligonucleotides DO1085 and DO1120 in clonal parasites was 
indeed wildtype sequence, this product generated from two separate PfM1-HAglmS 




4.2.5  PfA-M1 expression can be regulated by the addition of glucosamine 
 Considering that a clonal population of PfA-M1HAglms transgenic parasites is 
yet to be made, phenotypic analysis of this line cannot be performed; if a WT 
population is present, their expression of PfA-M1 will not be affected by the 
administration of glucosamine (GlcN). Despite this, it is still important to test that the 
parasites in the population that have incorporated the ribozyme into the 3’UTR can be 
regulated through the addition of GlcN. Analysis of PfA-M1 transcription on PlasmoDB 
revealed transcription peaks in the late ring stage of development (Figure 4.6). Hence 
the early ring stage was determined to be an appropriate time to administer GlcN for 
transcriptional knockdown. 
 Sorbitol-synchronised PfM1-HAglmS parasites at ring stage were cultured in 
the presence (+) or absence (-) of 2.5 mM GlcN as described in Chapter three. Protein 
was extracted from trophozoite stage parasites over two consecutive cycles. Western 
blot analysis of the protein lysates were probed with mouse anti-HA and rabbit anti-
HSP70 (loading control) (Figure 4.7). There was an obvious decrease in expression 
of PfA-M1 relative to the loading control in GlcN-treated parasites only, suggesting 
that GlcN is able to regulate PfA-M1 expression in the genetically modified parasites. 
This experiment has been performed only once because the line is not clonal, hence 
quantitation of the level of PfA-M1 knockdown could not be determined, nor has 















Figure 4.6 Expression analysis of PfA-M1 in three different P. falciparum strains 
RNA microarray was used to examine the expression of PfA-M1 (PF3D7_1311800) across 48 
individual 1-h time points from the intra-erythrocytic development cycle of P. falciparum strains 
3D7, Dd2 and HB3. Transcription peaks at the late ring-stage but otherwise appears 
















Figure 4.7 Protein regulation of HA-tagged M1 after addition of glucosamine 
Synchronised PfM1-HAglmS parasites either treated with (+) or without (-) 2.5 mM 
glucosamine (GlcN) were saponin lysed at trophozoite stage in cycle 1 (C1) or cycle 2 (C2). 
Western blot of protein pellets were probed with mouse anti-HA antibody and rabbit anti-







 The robust CRISPR-Cas9 system was used to determine if the Pfa-m1 locus 
can be targeted for gene disruption, and hence its contribution to parasite survival in 
the blood stages. Seven transfections were performed, using either one of two guide 
sequences in an attempt to create these knockout parasites, however, no parasites 
were detectable via microscopy even after extended periods of culturing. Given this 
extensive number of transfection attempts, the period of time the parasites were 
cultured for and the fact that the P47 locus (control) could be genetically deleted using 
the same approach within 24 days post-transfection, this data all points to PfA-M1 
having an essential role within the blood stage cycle of the parasite lifecycle, 
supporting previous findings (Dalal and Klemba, 2007; Zhang et al., 2018).  
 As PfA-M1 could not be genetically deleted using CRISPR/Cas9, the 
conditional knockdown line PfAM1-HAglmS, in which the protein can be post-
transcriptionally regulated, was generated in order to analyse function. However, the 
generation of transfectants in which the Pfa-m1 locus is genetically edited has proven 
difficult, as drug cycling to select for integrants and serial dilution cloning of the 
transgenic parasite population consistently returned parasites that were positive by 
PCR for the WT locus. As this was unexpected, different oligonucleotide combinations 
were used in the PCR to validate the presence of the WT locus, and amplified products 
from WT and transgenic parasites were sequenced. This confirmed that all PCR 
fragments were positive for the WT locus. Given that clonal populations generated 
from the parent line PfM1-HAglmS after four rounds of drug cycling were also positive 
for a WT locus, limiting dilution cloning was also performed under WR99210 selection 
(which is usually absent for the first ten days of culturing) but this also returned 
parasites positive by PCR for the WT locus. Potentially, the genetic locus of PfA-M1 
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may have duplicated either in the parental line or after transfection, such that one locus 
has incorporated the tagging construct and the other has not; this would account for 
PCR bands appearing for both the wildtype and transgenic locus. Alternatively, the 
construct may have integrated into the correct site and then recombined back out in 
some parasites, producing a mixed population of integrants and parasites replicating 
the plasmid episomally, both of which would survive drug pressure. Performing a 
Southern blot in the future will be important to confirm what is occurring at the genetic 
locus. Nevertheless, some parasites have correctly integrated the pM1-HAglmS 
construct into the Pfa-m1 locus, as revealed by Western blot and IFA analysis. 
 Interestingly, when Dalal and Klemba (2007) attempted to epitope tag the four 
P. falciparum aminopeptidases involved in haemoglobin digestion (PfA-M1, PfA-M17, 
PfA-M18 and PfA-APP), they reported that a clonal population of PfA-M1-YFP 
transgenic parasites was the most difficult to obtain of the four; however, they were 
able to generate one through serial dilution cloning (Dalal and Klemba, 2007). This 
may suggest that the locus is more difficult to tag than other loci. The tagging of the 
locus may also cause a growth defect, so that any wildtype parasites (or parasites 
replicating the plasmid episomally) quickly overgrow the population of integrants. 
Further attempts to clone the parasites by serial dilution will be undertaken so that a 
pure population of integrants can be generated for downstream analysis. In the interim 
it could be demonstrated that in parasites that have integrated the plasmid correctly, 
PfA-M1 can be efficiently regulated through the addition of GlcN, enabling phenotypic 
analysis to be performed once a clonal population of parasites has been obtained. A 
clonal population of the M1-HAglmS parasites can hopefully support findings that the 
locus is refractory to deletion using CRISPR-Cas9 in the future through the analysis 
of knockdown of the protein.                 
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 The PfA-M1HAglmS parasite lines will also be used in future experiments to 
characterise the aminopeptidase in parasites. For example, using HA antibodies, it will 
be possible to affinity purify the epitope tagged PfA-M1 to determine what other 
proteins are pulled down with it and whether these are food vacuole, cytosolic or 
nuclear proteins. It will also enable more IFAs to be performed to pinpoint more 
precisely the localisation of PfA-M1.  However, it should be noted that because the tag 
has been appended at the C-terminal end of the protein, there will be some limitations 
considering that PfA-M1 undergoes processing. In the literature, proteins of sizes 120, 
96 and 68 kDa have been characterised as possessing functional enzymatic activity, 
with the 68 kDa protein believed to be the form that cleaves amino acids from 
haemoglobin-derived peptides (Azimzadeh et al., 2010; Florent et al., 1998; Ragheb 
et al., 2011). The 120 kDa protein harbours an N-terminal transmembrane domain, 
and thus the N-terminus was deemed unsuitable for genetic tagging as it could 
interfere with insertion of PfA-M1 into the membrane; notably an N-terminal tag would 
also be cleaved off once the protein is processed to either the 96 kDa or 68 kDa forms. 
However, processing to the 68 kDa protein also removes the C-terminus and hence 
the HA tag in the PfM1-HAglmS line; thus, future work performed on the PfM1-HAglmS 
parasite line will only give insight into the localisation of the 120 and 96 kDa forms, 
and it will not be useful in studying the 68 kDa form. The IFA images generated to date 
indicate the 120 kDa form is not present in the food vacuole and the labelling in the 
cytoplasm could represent protein that is being trafficked to the food vacuole. Rabbit 
polyclonal antibodies to recombinant PfA-M1 are currently being generated that 
recognise the active site of PfA-M1, which is present in all forms of the protein. Thus 
by performing IFAs with the polyclonal PfA-M1 antibody and HA antibody and 
comparing the labelling patterns, it should be possible to discriminate where the 120 
94 
 
kDa and 68 kDa forms localise and the compartment in which processing occurs. It is 
important to note that the processing of PfA-M1 will not affect the knockdown 
experiments, since the ribozyme is effective at the mRNA level, and thus by effecting 
the transcription of the parental 120 kDa protein, all forms of the enzyme should be 



































Assessing the effect of novel therapeutics targeted 












 With drug resistance continuingly arising against current malaria therapeutics, 
development of new drugs against Plasmodium is paramount in the fight to achieve 
eventual malaria elimination. Both M1 and M17 have previously been targeted for the 
development of novel therapeutics, with a number of different inhibitor scaffolds being 
used to target the enzymes, either re-purposing existing or developing novel 
compounds (Deprez-Poulain et al., 2012; Drinkwater et al., 2016b; Kannan Sivaraman 
et al., 2013; Mistry et al., 2014; Skinner-Adams et al., 2007; Skinner-Adams et al., 
2012). The Medicines for Malaria Venture ‘Malaria Box’ has also been screened 
against recombinant PfA-M1 and PfA-M17 in an attempt to identify novel inhibitors 
(Paiardini et al., 2015). This large body of literature has focused on testing drugs 
against recombinant protein produced in bacteria and/or simply screening the efficacy 
(EC50) of the compounds against P. falciparum in vitro.      
 Work performed in Chapters three and four suggests that knockdown of PfA-
M17 within the parasite produces a severe phenotype and that PfA-M1 is essential to 
parasite survival within the erythrocytic cycle, respectively. While more analysis of the 
PfA-M17 CRISPR/Cas9 knockout line is required to determine its essentiality, this 
supports previous reports (Dalal and Klemba, 2007; Zhang et al., 2018), that both PfA-
M1 and PfA-M17 have the potential to be appropriate therapeutic targets.           
 In this Chapter, four novel PfA-M1 and PfA-M17 inhibitors were characterised 
in terms of their EC50 and the effect they have on P. falciparum survival in standard 
killing assays. The compounds analysed in this chapter arose from a structure-based 
drug design program aimed to develop competitive dual inhibitors of PfA-M1 and PfA-
M17, and are an advanced series of compounds based on previous studies 
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(Drinkwater et al., 2016b; Kannan Sivaraman et al., 2013; Mistry et al., 2014). All 
compounds were synthesized and provided by Professor Peter Scammells’ laboratory 
(Monash Institute of Pharmaceutical Sciences; MIPS). The compounds were tested 
for their aminopeptidase inhibition activity in Dr Sheena McGowan’s laboratory 
(Monash Biomedicine Discovery Institute). Of the four compounds, MIPS1700 and 
MIPS1778 were developed as potent dual inhibitors against both enzymes, while 
MIPS2571 and MIPS2673 are M17 and M1 selective inhibitors, respectively. Further 
analysis was also performed on MIPS1778, with the metabolomic profile of the 
parasites treated with this inhibitor compared to the metabolomic profile of parasites 
after protein knockdown of PfA-M17 in an attempt to compare and understand the 
changes seen with these two treatments, and to attempt to map these changes to 
particular processes within the parasite. 
 
5.2 Results 
5.2.1 Determining the EC50 of MIPS1700 and its effect on parasite growth 
 The EC50 is the concentration of a drug or compound that gives 50 % of its 
maximal effect; in this case, it is the concentration at which 50 % of parasites are killed 
within a standard 72 hour killing assay using SYBR Green I (Smilkstein et al., 2004). 
Serial dilutions of the compound MIPS1700 were made from an initial concentration 
of 3200 nM and incubated with the parasites before detecting parasite survival. 
Parasite cultures not treated with compound and uninfected red blood cells (RBCs) 
were used as controls. Growth percentage curves were plotted against the log of the 








Figure 5.1 Effect of MIPS1700 on parasite growth 
(A) Killing action of MIPS1700 as determined by SYBR Green I assay. The % growth was 
plotted against the log of varying concentrations of the drug (nM) calculated in GraphPad 
Prism 7. The EC50 was calculated as 97.84 nM from 4 biological replicates performed in 
triplicate. Error bars represent standard deviation. (B) Synchronised parasites at 4 hrs post-
invasion were treated with either 5 x or 10 x EC50 over two cycles (C1, cycle 1; C2, cycle 2). 
The control was treated with the final concentration of DMSO from the 10 x EC50 treatment. 
Representative Giemsa-stained smears show parasites stalling at either trophozoite (5 x EC50) 




calculated to be 97.84 ± 3.79 nM (Figure 5.1A). Four biological replicates in triplicate 
were performed.  
 After determination of the EC50, analysis of the compound’s effect on parasite 
growth was performed. In these assays, heparin-synchronised 3D7 parasites were 
allowed to reinvade RBCs for a four-hour window before being treated with either 5 x 
or 10 x EC50 of compound (Figure 5.1B); as a control, the final concentration of DMSO 
present in the 10 x EC50 of compound was incubated with parasites. Giemsa-stained 
smears were made every six hours. The 5 x EC50 treated cultures showed an obvious 
stalling of growth when compared to the control cultures and only reached mid- to late 
trophozoite stage (~34 hours post reinvasion) at the same time the control cultures 
had reinvaded into cycle 2. Cultures treated with 10 x EC50 displayed an even more 
severe phenotype, with parasites not progressing past ~22 hours post reinvasion.  
5.2.2 Determining the EC50 of MIPS1778 and its effect on parasite growth 
 The EC50 for MIPS1778 was determined the same way as described for 
MIPS1700, with untreated parasite cultures and uninfected RBCs used as controls. 
Serial dilutions of this compound were made from an initial concentration of 1000 nM 
for the 72-hour killing assay. The EC50 was calculated to be 38.66 ± 4.38 nM from four 
biological replicates performed in triplicate (Figure 5.2A). 
 The calculated EC50 was then used to assess the effect of MIPS1778 treatment 
would have on parasite growth and survival. Parasite growth was severely impacted 
in both the 5 x and 10 x EC50 treatments, with neither treatment group proceeding past 
the earliest stages of ring development (~16 hours post reinvasion) when compared 









Figure 5.2 Effect of MIPS1778 on parasite growth 
(A) Killing action of MIPS1778 as determined by SYBR Green I assay. The % growth was 
plotted against the log of varying concentrations of the drug (nM) calculated in GraphPad 
Prism 7. The EC50 was calculated as 38.66 nM from 4 biological replicates performed in 
triplicate. Error bars represent the standard deviation. (B) Synchronised parasites at 4 hrs 
post-invasion were treated with either 5 x or 10 x EC50 over two cycles (C1, cycle 1; C2, cycle 
2). The control was treated with the final concentration of DMSO from the 10 x EC50 treatment. 
Representative Giemsa-stained smears show parasites stalling at ring stage of cycle 1 for 
both the 5 x and 10 x EC50 treatments.  
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5.2.3 Determining the EC50 of MIPS2571 and its effect on parasite growth
 The EC50 was determined for MIPS2571 as described above for previous drugs. 
The drug was initially serially diluted from 14.496 µM. The EC50 was calculated to be 
326.7 ± 15.16 nM from four biological replicates performed in triplicate (Figure 5.3A). 
 Assessment of the effect of MIPS2571 on parasite growth was again 
determined using heparin-synchronised parasites cultured with DMSO or with 
compound at 5 x or 10 x EC50. Treatment with 5 x the EC50 resulted in a delay in 
parasite growth, with a limited number of parasites reaching schizogony, ~12 hours 
behind the control. The schizonts that did form, however, appeared atypical, with fewer 
merozoites and the parasite cytosol appearing highly vacuolated. Interestingly, no 
rings were visible, which would indicate the merozoites were incapable of invading 
RBCs and commencing the next cycle (cycle 2). The growth delay was even more 
severe after treatment with 10 x EC50, with parasites exhibiting a ~24 hours lag in 
growth behind the control group (Figure 5.3B). Haemozoin crystal could be seen 
forming in both treatment groups via microscopy, indicating that the initial stages of 
haemoglobin digestion had occurred. It should be noted that the control cultures 
(treated with the same final concentration of DMSO as is in the 10 x EC50 drug 
treatment group) in this case also appeared to exhibit a slight growth delay when 
compared to the control cultures for other drug treatment time courses. 
5.2.4 Determining the EC50 of MIPS2673 and its effect on parasite growth 
 The EC50 was determined for MIPS2673 as described above for previous 
compounds. The drug was initially serially diluted from 3136 nM. The EC50 was 
calculated to be 324.1 ± 7.36 nM from four biological replicates performed in triplicate 









Figure 5.3 Effect of MIPS2571 on parasite growth 
(A) Killing action of MIPS2571 as determined by SYBR Green I assay. The % growth was 
plotted against the log of varying concentrations of the drug (nM) calculated in GraphPad 
Prism 7. The EC50 was calculated as 326.7 nM from 4 biological replicates performed in 
triplicate. Error bars represent the standard deviation. (B) Synchronised parasites at 4hrs post-
invasion were treated with either 5 x or 10 x EC50 over two cycles (C1, cycle 1; C2, cycle 2). 
The control was treated with the final concentration of DMSO from the 10 x EC50 treatment. 
Representative Giemsa-stained smears show delay in parasite maturation, only reaching 









Figure 5.4 Effect of MIPS2673 on parasite growth 
(A) Killing action of MIPS2673 as determined by SYBR Green I assay. The % growth was 
plotted against the log of varying concentrations of the drug (nM) calculated in GraphPad 
Prism 7. The EC50 was calculated as 324.1 nM from 4 biological replicates performed in 
triplicate. Error bars represent the standard deviation. (B) Synchronised parasites at 4hrs post-
invasion were treated with either 5 x or 10 x EC50 over two cycles (C1, cycle 1; C2, cycle 2). 
The control was treated with the final concentration of DMSO from the 10 x EC50 treatment. 
Representative Giemsa-stained smears show parasites stalling and dying at early trophozoite 






































with parasites reaching early trophozoite stage (~22-28 hr old), roughly 18 hours 
behind the DMSO-treated control. There early trophozoites did not appear to proceed 
much further in terms of growth and at ~58-hour time point many appeared as small, 
dark dots within RBCs when Giemsa-stained, representative of dead parasites. No 
parasites grew past this time point. Treatment with 10 x EC50 had a more severe effect 
on parasite growth, with no parasites seen progressing past ~22-hour old rings when 
compared to the control (Figure 5.4B). Parasites from both treatment groups appeared 
to have haemozoin production, again indicating that the initial stages of haemoglobin 
digestion had occurred. All EC50 values determine in this study for the four novel 
inhibitors analysed have been summarised in Table 5.1. 
5.2.5 Metabolite comparison of PfA-M17 knockdown and treatment with 
MIPS1778 
 Metabolomics analysis aims to characterise all the metabolites within a parasite 
population, and map changes in different pathways when compared to controls. In this 
experiment, untargeted liquid chromatography - mass spectrometry (LC-MS) analysis 
of P. falciparum parasites treated with MIPS1778 or after knockdown of PfA-M17 using 
2.5 mM glucosamine (GlcN) was performed and analysed by Dr. Ghizal Siddiqui 
(Creek laboratory, MIPS) (Figures 5.5, 5.6 and 5.7). For the drug treatment 
experiment, heparin was used to synchronise P. falciparum 3D7 wildtype (WT) 
parasites within a 4 hr window. When the parasites reached ~20 h old trophozoites, 
they were treated with the compound MIPS1778 at 10 x the EC50 for one hour, after 
which they were harvested for analysis and metabolites extracted (1778_treated). For 
the PfA-M17 knockdown experiment, PfM17-HAglmS clone 2E7 was treated with 2.5 
mM glucosamine at ring-stage in cycle 1 (M17_KD_gln) before being allowed to 
reinvade into the next cycle (cycle 2); once they reached ~20 hour old trophozoites in 
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cycle 2, they were harvested for analysis and metabolites extracted. Three separate 
control cultures were included in this experiment: 3D7 either treated with 2.5 mM GlcN 
(3D7_gln) or left untreated (3D7), and the 2E7 parasite line left untreated (M17_KD). 
Each treatment group and the controls were performed in technical triplicates. After 
parasite harvest and extraction of the metabolites, the samples were transported on 
dry ice to Dr. Ghizal Siddiqui at MIPS.  
 Sparse partial least squares discriminant analysis performed on the 30 different 
metabolites that were identified revealed a distinct difference between the knockdown 
of PfA-M17 and the treatment of MIPS1778 (Figure 5.5). Each technical replicate is 
represented by a dot on the graph, with treatment groups colour coded and grouped 
together with shading. The three control groups all clustered together, indicating that 
they had a similar metabolite profile. However, the metabolites from wildtype parasites 
treated with MIPS1778 and 2E7 parasites treated with GlcN did not cluster together, 
suggesting that they have vastly different metabolite profiles.  
 Heat map analysis also confirmed a difference between the metabolites after 
MIPS1778 or GlcN treatment (Figure 5.6). A significant increase in peptides was 
obvious for both treatment groups (indicated in red), however, there was a different 
pattern in the heatmaps, indicating different peptides were affected in the knockdown 
and the MIPS1778 treated parasites. Significant increases in a number of unknown 
metabolites were also evident after PfA-M17 knockdown, which were not apparent in 
the MIPS1778 treatment group. The differences observed in carbohydrate metabolism 
can be attributed to the use of GlcN, as changes seen in the 2E7 GlcN treated 







Figure 5.5 Sparse partial least squares – discriminant analysis of glucosamine or drug 
treated parasites 
Heparin-synchronised PfA-M17HAglmS clone 2E7 or wildtype 3D7 parasites were either 
treated with 2.5 mM glucosamine (GlcN) or with 10 x the EC50 of the drug MIPS1778 
(1778_treated), respectively. 3D7 cultured in the presence of 2.5 mM GlcN (3D7_gln), and 
3D7 or 2E7 cultured in the absence of GlcN (3D7 and M17_KD, respectively) served as 
controls. Sparse partial least squares – discriminant analysis (sPLSDA) algorithms were run 
with increasing numbers of metabolites in each component. This final sPLSDA plot was 













Figure 5.6 Heat map indicating changes in metabolites in treated and untreated parasite 
lines 
Heparin-synchronised 2E7 or 3D7 were either treated with glucosamine (GlcN) or with the 
drug MIPS1778 (1778_treated) respectively. 2E7 treated without GlcN (M17_KD), as well as 
3D7 treated with (3D7_gln) or without GlcN (3D7) served as controls. Red indicates a high 
abundance, blue a low abundance and yellow an intermediate abundance. An increase of 
peptides can be seen after knockdown of PfA-M17 in the parasite line 2E7 (M17_KD_gln) and 
in 3D7 after treatment with MIPS1788 (1778_treated), however both of these treatment groups 
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Figure 5.7 Comparison of peptide changes between glucosamine and drug treated 
parasites  
Heparin-synchronised 2E7 parasites were treated with 2.5 mM glucosamine (M17_KD_gln) 
and 3D7 parasites were treated with the drug MIPS1778 at 10 x EC50 (1778_treated); 2E7 
grown in the absence of glucosamine (M17_KD) served as the control. Analysis performed 
revealed significant changes in peptides after treatment, some which could be mapped to the 
(A) alpha and (B) beta chains of haemoglobin; however some did not map to either chain (C).   
Hbα 1778_treated M17_KD M17_KD_gln
EA 2.28 1.00 8.81
PA 3.02 1.00 3.61
VD 0.86 1.00 2.91
PT 1.70 1.00 2.18
HK 6.09 1.00 1.72
KV 2.94 1.00 1.62
PVNF 2.63 1.00 1.26
SD 2.72 1.00 1.14
KG 5.03 1.00 0.79
KA 6.09 1.00 0.78
LR 1.61 1.00 0.54
RV 1.57 1.00 0.31
KL 1.29 1.00 0.26
Hbβ 1778_treated M17_KD M17_KD_gln
PEE 6.25 1.00 36.49
PE 1.19 1.00 28.94
ES 2.53 1.00 3.59
EV 1.87 1.00 3.15
HLD 1.07 1.00 2.99
SFGD 5.38 1.00 1.95
PPVQ 2.11 1.00 1.85
EL 2.09 1.00 1.52
DNLK 1.14 1.00 1.50
GR 4.39 1.00 0.42
Unknown 1778_treated M17_KD M17_KD_gln
KED 1.48 1.00 28.36
PGG 3.03 1.00 8.65
ED 1.08 1.00 1.62
RA 15.99 1.00 1.46
TE 0.84 1.00 1.20
EQ 1.37 1.00 1.03
GGGPK 2.15 1.00 0.95
GHVDD 1.66 1.00 0.73
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A number of significantly different peptide metabolites were identified between the 
wildtype parasites treated with MIPS1778 and 2E7 GlcN treated parasites, which were 
analysed further. These treatment groups were compared to the untreated 2E7 control 
group, which was represented as 1.00, with increases (red) and decreases (blue) 
outlined for each treatment group. Amino acid sequences that appeared to have the 
greatest changes compared to the control were identified are presented in Figure 5.7. 
Many of these peptides could be mapped to either the alpha or beta chains of 
haemoglobin (13 for alpha, 10 for beta), indicating that the effect of MIPS1778 
treatment on wildtype parasites or 2E7 GlcN treated parasites had a build-up of 
peptides not able to be effectively cleaved into free amino acids (Figure 5.7 A & B). 
For the alpha chain peptides, all but one was a dipeptide, however, for the beta chain, 
only five were dipeptides (Figure 5.7 A & B). There were also eight peptides that did 
not map to either chain (Figure 5.7 C), and thus could have originated from a different 












 All four compounds analysed here displayed an EC50 within the nanomolar 
range, with the EC50 for both MIPS1700 and MIPS1778 under 100 nM. In comparison, 
the current front-line therapeutic, artemisinin, has been shown to have an EC50 
between 3 and 108 nM when tested against a range of different P. falciparum strains 
in vitro (Alin et al., 1990).  
 The most potent inhibitor MIPS1778, with the lowest EC50 of 38.66 nM, was 
most effective in culture, as treated parasites did not proceed past ~16 hour rings for 
both the 5 x and 10 x EC50 concentrations when compared to the DMSO control. As 
this is a dual inhibitor targeted at both PfA-M1 and PfA-M17, this effect on parasite 
growth is not surprising; both enzymes are predicted to play a role in the final and 
essential process of haemoglobin digestion, with inhibition of both aminopeptidases 
potentially rendering amino acid cleavage extremely limited. The inability for parasites 
to cleave free amino acids would not only affect protein anabolism, it could also affect 
the importation of the essential amino acid isoleucine, which is not found in 
haemoglobin and thus has to be imported by the parasite (Liu et al., 2006; Martin and 
Kirk, 2007; Skinner-Adams et al., 2010), as well as the osmotic regulation within the 
RBC (Lew et al., 2004); this would explain the severe phenotype observed.  
 The other dual inhibitor MIPS1700, with an EC50 of 97.84 nM, also led to 
delayed parasite growth, with a titration effect seen between the 5 x and 10 x EC50 
concentrations. Parasites treated with either concentration of inhibitor proceeded to at 
least the ~22 hour stage of development when compared to the DMSO control. At this 
point, the 10 x EC50 culture stalled and did not develop any further. The 5 x EC50 culture 
developed to ~34 hour trophozoites, with haemozoin crystal visible via microscopy, 
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indicating that the earliest stages of haemoglobin digestion had occurred. As this 
inhibitor has a higher EC50compared to MIPS1700, it may not be acting as effectively 
within the parasites, allowing them to proceed further in the lifecycle. Future 
experiments on longer time courses will help determine whether these trophozoites 
are viable and can develop further, and varying the duration of drug treatment and 
testing for culture recovery after drug removal are some approaches that can be used 
to test this and the potency of the compounds.  
 The inhibitors targeted against PfA-M17 (MIPS2571) or PfA-M1 (MIPS2673) 
showed somewhat different phenotypes when compared to the dual inhibitors, as well 
as one another. Cultures treated with MIPS2571 showed a delay in parasite 
development when compared to the DMSO control. The parasites in the 10 x EC50 
treated cultures did not appear to develop past trophozoite stage, but the cultures 
treated with 5 x EC50 did develop into schizonts. These schizonts appeared abnormal 
and the numbers of merozoites forming per schizont appeared to be lower, with the 
parasites looking highly vacuolated; however, this was not quantified and further 
analysis is still required. Haemozoin was again distinguishable by microscopy, 
indicating that the earliest stages of haemoglobin digestion had occurred, as expected. 
If haemoglobin is not completely digested by the parasite, this could affect the osmotic 
regulation within the RBC, as well as provide less space within the RBC for the parasite 
to grow. Interestingly, no ring stage parasites could be seen at this point, but there 
was an obvious reduction in parasitemia (data not shown), suggesting that perhaps 
the schizonts were unable to burst, or any released merozoites were unable to 
reinvade into new RBCs. Further investigation is needed to tease out the phenotype 
of parasites treated with this compound; for example longer time course experiments 
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involving parasitemia counts and determining the number of merozoites within 
schizonts as well as invasion assays.  
 In comparison to the M17 inhibitor, the M1 inhibitor MIPS2673 produced a much 
more severe phenotype on parasite growth and development. Cultures treated with 10 
x EC50 did not proceed past ~16 hours post reinvasion when compared to the control, 
similar to what was seen in the 10 x EC50 treatment groups for both dual inhibitors, 
MIPS1700 and MIPS1778. This suggests that the major cause of the severity of these 
dual inhibitors on parasite growth is potentially via their inhibition of PfA-M1, and that 
inhibition of PfA-M17 is not responsible for the parasite stalling at the early stages of 
growth. This is also supported by the potential deletion of the Pfa-m17 locus previously 
described in Chapter three, as well as by the significant knockdown of the protein as 
described in Chapter three, which resulted in parasite stalling and death, but not until 
trophozoite stage. Treatment with 5 x the EC50 of MIPS2673 saw parasites develop 
slightly further into the lifecycle, with parasites reaching early trophozoite stage (~22-
28 hours post reinvasion when compared to the control). At this point, parasites 
appeared to be dying, as represented by the image at 58 hours post reinvasion (Figure 
5.4B); microscopy revealed shrivelled and collapsed parasites. This indicates that the 
effect of the compound either occurs at the trophozoite stage, or that any earlier effect 
doesn’t cause parasite death until this stage. As PfA-M1 is playing a role in cleavage 
of amino acids in the final stages of haemoglobin digestion (Harbut et al., 2011), which 
is believed to occur maximally during the trophozoite stage to allow room for the rapidly 
expanding parasite, it is not surprising that parasites are unable to proceed past this 
point. This is in sharp comparison to inhibition with the M17-specific inhibitor 
MIPS2571, where parasites could grow until schizogony. This potentially could be 
explained by the ability of PfA-M1 to cleave the amino acid leucine, which is the major 
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substrate of PfA-M17 within the parasite, and thus PfA-M1 may be partially able to 
complement PfA-M17 function.  
 As with any drugs under development, there is always the possibility that the 
four compounds described above have some off-target effects, and in the future it will 
be important to test for these. Already we have developed a conditional knockdown 
parasite line for PfA-M17, so it will now be possible to conduct time course analyses 
to compare the addition of PfA-M17 inhibitors to knocking down expression of PfA-
M17 using GlcN. In Chapter three, it was shown that the parasite line 2E7, which is 
clonal for the integration of pM17-HAglmS, proceeded to schizogony even after 
significant knockdown of the enzyme, but exhibited limited reinvasion into the next 
cycle. This is a similar phenotype to that observed with MIPS2571, a drug specifically 
designed to target PfA-M17. This suggests that MIPS2571 is acting on-target in 
culture. Further validation of this could be obtained by performing a concurrent time 
course analysis of the 2E7 line rather than the parental 3D7 wildtype line treated with 
MIPS2571 or 2.5 mM GlcN, or both the drug and GlcN together. Once a clonal line of 
M1-HAglmS has been generated, similar experiments can also be performed with 
compounds designed to target PfA-M1. If a clonal line can also be generated for the 
knockout of the Pfa-m17 locus, and this line is then used to transfect the pM1-HAglmS 
for targeting into the Pfa-m1 locus to enable conditional regulation of PfA-M1, then 
further validation of the dual inhibitors can also be conducted. Moreover, it will be 
possible to discern whether PfA-M1 function overlaps with that of PfA-M17.  
 Herein metabolomic analysis was used to compare the effect of MIPS1778 
treatment to the knockdown of PfA-M17. As MIPS1778 is a dual inhibitor, it is not 
surprising that the metabolomic profile was different when compared to knocking down 
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just PfA-M17 expression. As expected, there was significant increase in peptides 
within the parasite in both circumstances, indicating that the cleavage of free amino 
acids was hindered with both MIPS1778 drug treatment and PfA-M17 knockdown. 
Again as expected, many of these significantly changed peptides could be mapped to 
either the alpha or beta chains of haemoglobin; however, there was also a subset of 
peptides generated that did not map to either chain. These peptides also appear to be 
different between the two treatment groups. The peptides significantly increasing after 
the knockdown of PfA-M17 could potentially be indicative of an additional cleavage 
role for this enzyme besides haemoglobin digestion. The unknown peptides 
significantly increased after the treatment of MIPS1778 may be due to the inhibition of 
PfA-M1, the other enzyme that this drug is targeted at. The experimental design must 
also be considered, as 2E7 parasites were treated with GlcN over one cycle before 
being harvested at ~22 hours post-invasion for analysis, while 3D7 parasites were only 
treated with MIPS1778 for one hour prior to harvesting, also at ~22 hour post-
reinvasion; this was an attempt to capture the metabolomic profile at a similar time at 
which the phenotype was occurring, but may also contribute to the different metabolite 
profiles found. In the future, the development of a clonal PfM1-HAglmS line will allow 
further comparisons between treatment with MIPS1778 in parasite lines that are 
expressing or are depleted of PfA-M1.  It should also be noted that MIPS1778 was the 
only drug to be tested in metabolomics because this was the only compound that was 
available at the time in sufficient quantity to perform the experiments. Future 
experiments using all four compounds compared to either/or the PfA-M1 and PfA-M17 
knockdown parasite lines to assess the affected metabolites will be required to 
determine whether the compounds have off-target effects and to further tease out the 
























 This study used a variety of different methods to characterise the function and 
essentiality of the two aminopeptidases PfA-M1 and PfA-M17 in P. falciparum to 
further validate them as drug targets. Attempts to genetically delete the Pfa-m1 locus 
using CRISPR/Cas9 proved futile, with no parasites returning post-transfection 
despite extended periods of culturing. This was not the case for PfA-M17, with 
parasites positive for gene knockout by PCR recovered on multiple occasions. In 
contrast, significant knockdown of PfA-M17 using the conditional riboswitch system 
resulted in stalling of parasite development, limited reinvasion capacity and eventual 
death. A conditional riboswitch knockdown line for PfA-M1 was also generated, with a 
clonal population yet to be established for phenotypic analysis. Lastly, novel inhibitors 
targeted to PfA-M1 and/or PfA-M17 were analysed for their effectiveness at killing P. 
falciparum in vitro and phenotypes determined; all inhibitors showed the ability to kill 
parasites at either the 5 x or 10 x EC50, with the dual inhibitors being the most 
efficacious. Further analysis on one of these dual inhibitors showed that peptide 
changes after drug treatment, as analysed by metabolomics analysis, could be 
mapped to haemoglobin, as could a number of metabolite changes in parasites after 
knockdown of PfA-M17. For both these treatments, a subset of peptides with 
significant changes did not map to haemoglobin, suggesting that treatments may also 
be having an effect on a pathway not involved in haemoglobin digestion.    
 Previous attempts to delete PfA-M1 have all been unsuccessful, but the 
methods used have been untargeted (Zhang et al., 2018) or lack a degree of 
robustness (Dalal and Klemba, 2007), such that if a fitness cost is incurred there is a 
low success rate of recovering transfectants. Nevertheless, these findings have been 
further validated by the inability to knockout the homologous gene in the murine model 
P. berghei (Lin et al., 2015). The findings from Chapter four using the targeted and 
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robust CRISPR-Cas9 system is consistent with all of these studies, allowing 
confirmation of the essentiality of this enzyme in P. falciparum. PfA-M1 is implicated 
in the final stage of haemoglobin digestion, and is the aminopeptidase indicated in the 
cleavage of the largest subset of amino acids (Dalal et al., 2012); the other three 
aminopeptidases involved in end-stage haemoglobin digestion (PfA-M17, PfA-M18 
and PfA-APP) have a more specific substrate profile (Drinkwater et al., 2016a; 
McGowan et al., 2010; Spicer et al., 2014). It is not surprising, therefore, that PfA-M1 
is an essential protein in the erythrocytic life cycle of P. falciparum.  
 The inhibitor MIPS2673 was developed to target both M1 from P. falciparum 
and P. vivax and is one of the novel inhibitors characterised in this study; its in vitro 
testing is vital to understanding not only how the inhibitor itself works, but also the 
function(s) that the enzyme may be performing within the parasite. Cultures treated 
with 10 x the EC50 calculated in this study did not proceed past the early ring stage of 
development, and although the 5 x EC50 cultures did proceed to the early trophozoite 
stage, the parasites subsequently died. This is in contrast to a number of phenotypes 
previously described in the literature when Plasmodium M1 has been specifically 
targeted. Harbut et al. (2011) identified an inhibitor selective for PfA-M1 over PfA-M17 
via recombinant protein screening. When tested in vitro, this inhibitor caused a 
parasite growth delay, swelling of the food vacuole and eventual death at ~60 hours 
post reinvasion (Harbut et al., 2011). Bounaadja et al. (2017) developed a specific 
Plasmodium M1 inhibitor and tested it in vitro against P. falciparum. Phenotypic 
analysis showed moderate swelling of the food vacuole in trophozoites, slowing of 
growth and blocking of schizont development (Bounaadja et al., 2017). Both of these 
studies showed that parasites could develop much further than described here after 
treatment with MIPS2673. Alternatively, the drugs in these two studies may not be as 
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potent, specific or on-target as the MIPS2673 inhibitor described herein. It is still 
possible that MIPS2673 has some off-target effects, and the future development of a 
clonal PfA-M1 knockdown line will allow comparison between the knockdown of the 
protein and the drug treatment to specifically test for this.  
 There is additional conjecture in the literature about PfA-M1 harbouring an 
additional role within the parasite. This arises not only from the ability of parasites 
treated with the previously described specific inhibitors to reach schizogony, far past 
when haemoglobin digestion is occurring (Bounaadja et al., 2017; Harbut et al., 2011), 
but also from the localisation of the protein to the nucleus when fused to an YFP tag 
(Dalal and Klemba, 2007). In this current study, the introduction of a triple 
hemagglutinin tag to the C-terminus of PfA-M1 allows probing of the tagged enzyme 
that can be visualised using fluorescent microscopy but only enables localisation of 
the 120 kDa form as the C-terminus is removed upon processing of the proteins. Initial 
imaging could confirm that the line was correctly expressing the tag but future detailed 
imaging using both HA antibodies and polyclonal rabbit PfA-M1 antibodies will need 
to be undertaken to definitely determine the localisation of the different forms of the 
protein. Further analysis of this line, once clonal, will also help in understanding the 
function of the enzyme via the protein knockdown. Time course analysis, metabolomic 
analysis and potentially peptidomic analysis will be used to identify the pathways that 
are affected by the knockdown, with haemoglobin digestion expected to be the most 
effected.  
 Interestingly, previous attempts to delete PfA-M17 have also been 
unsuccessful (Dalal and Klemba, 2007; Zhang et al., 2018). The CRISPR-Cas9 
system used here, however, did return parasites positive by PCR for knockout of the 
genetic locus, in line with the ability to knockout this locus in the rodent malarial 
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species P. berghei (Lin et al., 2015). Whether this genetic deletion has occurred 
correctly still requires investigation. Ultimately, a Southern Blot comparing the 3D7 
parental line with the two clonal lines from the different knockout transfections will 
allow confirmation of what has happened to the genetic locus. If these parasites 
harbour a truncated version of PfA-M17, then it will be important to perform qRT-PCR 
to see what effect this has on the expression of the other aminopeptidases, particularly 
PfA-M1, which has the ability to cleave the widest range of amino acids from peptides; 
an increase in its transcription may complement the loss of PfA-M17.   
 That PfA-M17 can potentially be knocked out is in contrast to the significant 
phenotype observed in Chapter three after knockdown of the protein using the 
ribozyme system. This resulted in a severe parasite growth delay, limited reinvasion 
into the following cycle and parasite death. The essentiality of PfA-M17 was further 
supported by findings in Chapter five using the inhibitor MIPS2571 developed to target 
this enzyme. Treated cultures proceeded to schizogony, however there appeared to 
be fewer merozoites, and schizonts exhibited altered morphology compared to the 
control, and again no reinvasion into the following cycle was seen. These schizonts 
displayed a similar morphology to the limited number of schizonts that formed after 
PfA-M17 knockdown, and future analysis in which PfA-M17 knockdown performed 
alongside MIPS2571 drug treatment will be important to determine if the drug has any 
off-target effects. This phenotype may be a consequence of parasites struggling to 
reach this later stage of development due to amino acid depletion, and thus limiting 
the number of merozoites in an attempt for some parasites to reach the next cycle 
(Counihan et al., 2017). Alternatively, PfA-M17 may be playing an additional role in 
this later stage of development that cannot be complemented by one of the other 
aminopeptidases, whilst the role it plays in haemoglobin digestion may be able to be 
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compensated for, perhaps by PfA-M1. The phenotypes observed after PfA-M17 
knockdown and treatment with MIPS2571 are in contrast to the phenotype seen by 
Harbut et al. (2011), where treatment with a Bestatin-based inhibitor designed to 
specifically target PfA-M17 resulted in ring-stage arrest, even before haemoglobin 
digestion could be detected (Harbut et al., 2011). As Bestatin is known to be a general 
aminopeptidase inhibitor, off-target effects cannot be ruled out.  
 If, however, genetic knockout of PfA-M17 is possible, there are implications into 
the suitability of the enzyme as a drug target. Theoretically, as PfA-M1 has the ability 
to cleave PfA-M17’s main substrate leucine, then inhibiting both of them could result 
in a loss of the majority of amino acid cleavage from haemoglobin-derived peptides 
within the parasite, leading to amino acid deprivation, dysregulation of plasma 
osmolarity and parasite death. This has previously been explored, with dual inhibitors 
discovered via repurposing of developed drugs (Drinkwater et al., 2015) or developed 
to target both enzymes (Drinkwater et al., 2016b). Drinkwater et al. (2016b) showed a 
number of synthesised inhibitors had EC50 values within a low nanomolar range, but 
time course analysis was not performed. In this current work, the two dual inhibitors 
MIPS1700 and MIPS1788 were found to have EC50’s less than 100 nM, with both 
inhibiting growth at the early ring stage of the parasite when treated with the 10 x EC50. 
Further analysis is still required on these drugs. For example, it will be critical to 
determine whether parasites cultured with the drugs in vitro can readily develop 
resistance against them, as well as to test the drugs on human cell lines. Testing in in 
vivo models of malaria infection to look at toxicity and drug pharmacokinetics will be 
vital in determining whether they will be potential therapeutics for the future. It will also 
be of value to compare the compounds to a clonal PfA-M17 knockout parasite line (if 
possible) co-transfected with the PfA-M1 riboswitch plasmid, as knockdown of the 
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latter would then result in a loss of both enzymes in this parasite line; hopefully the 
resulting phenotype would mimic treatment with the dual inhibitors, thus confirming 
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